FLUORESCENCE IMMUNOASSAYS USING FLUORESCENT DYES FREE OF AGGREGATION AND SERUM BINDING

Abstract: Fluorescence immunoassays methods are provided which use fluorescent dyes which are free of aggregation and serum binding. Such immunoassay methods are thus, particularly useful for the assay of biological fluids, such as serum, plasma, whole blood and urine.

Description: DESCRIPTION * Fluorescence Immunoassays Using Fluorescent Dyes Free of Aggregation and Serum Binding β This application is a continuation-in-part of U.S. application Serial No. 07/856,176, filed March 23, 1992, which is a continuation-in-part of U.S. application Serial No. 701,449, filed May 15, 1991, which is a continuation- 5 in-part of U.S. application Serial No. 523,601, filed May 15, 1990. U.S. application Serial No. 07/856,176, filed March 23, 1992, is also a continuation-in-part of U.S. application Serial No. 701,465, filed May 15, 1991, which is a continuation-in-part of U.S. application Serial 10 No. 524,212, filed May 15, 1990. Field of the Invention The present invention relates to methods for deter¬ mining the presence or amount of antigenic substances in samples. The invention is directed to fluorescence 15 immunoassays using particular fluorescence dyes which are essentially free of aggregation and serum binding and, thus, are particularly suited for the measurement of antigenic substances in biological materials such as serum, plasma and whole blood. 20 Background of the Invention Publications and other reference materials referred to herein are incorporated herein by this reference. The determination of the presence or amount of anti¬ genic substances is commonly performed by immunoassay. 25 Immunoassay techniques are based on the binding of the antigenic substance being assayed (the "target analyte") and a receptor for the target analyte. Either the target analyte or the receptor may be labeled to permit detec¬ tion. Various labels have been employed for use in 30 immunoassays, including radioisotopes, enzymes and fluorescent compounds. Many different types of immuno¬ assays are known in the art, including competitive inhibition assays, sequential addition assays, direct "sandwich" assays, radioallergosorbent assays, radio- immunosorbent assays and enzyme-linked immunosorbent assays. The basic reaction underlying most immunoassays is the binding of certain substance, termed the "ligand" or "analyte", by a characteristic protein (receptor) to form a macromolecular complex. These binding processes are reversible reactions, and the extent of complex formation for particular analyte and receptor concentrations is regulated by an equilibrium constant according to the law of mass action. Thus, at equilibrium, some of the analyte always exists unbound (free) . In a competitive inhibition immunoassay, the unknown quantity of target analyte in the sample competes with a known amount of labeled target analyte for a limited number of receptor binding sites. The reagents usually consist of a labeled target analyte, such as an antigen, and a solid phase coupled receptor, such as an antibody. The antigen to be assayed competes with the labeled anti¬ gen for binding sites on the coupled antibodies. The concentration of target analyte present in the sample can be determined by measuring the amount of labeled target analyte — either "free" or "bound." This is an indirect assay method where the amount of labeled antigen bound to the antibodies is inversely correlated with the amount of antigen in the test solution. Thus, low concentrations of target analyte in the sample will result in low concentra¬ tions of "free" labeled target analyte and high concentra¬ tions of "bound" labeled target analyte, and vice versa. The amount of "free" or "bound" labeled target analyte is measured using a suitable detector. Quantitative determi- nations are made by comparing the measure of labeled tar¬ get analyte with that obtained for calibrated samples containing known quantities of the target analyte. This method has been applied to the assay of a great number of different polypeptide hormones, enzymes and immunoglobu- lins. This method may also be used as a total liquid system. It is apparent to those skilled in the art that it is not absolutely necessary that the labeled analyte be iden¬ tical to the unlabeled target analyte. If there is a dif¬ ference between the two, for example, if the labeled ana¬ lyte is an analog of the target analyte, the reaction between labeled and unlabeled analytes may be considered to be competitive for the receptor binding sites; and the reaction will still provide quantitative answers, provid¬ ing the difference in affinity of the analytes is not too great. Whether or not true competition occurs in a system consisting of labeled analyte, unlabeled analyte, and receptor depends on the nature of the labeled analyte and the specificity of the receptor. In sequential addition assays, the reagents used are the same as in the competitive inhibition assay described above. However, instead of incubating them at the same time, the unlabeled antigen is first incubated with the antibody, then the labeled antigen is added. Direct immunoassay systems are also known in the art. Such assays, also termed "immunometric" assays, employ a labeled receptor (antibody) rather than a labeled analyte (antigen) . In these assays the amount of labeled receptor associated with the complex is proportioned to the amount of analyte in the sample. Immunometric assays are well- suited to the detection of antigenic substances which are able to complex with two or more antibodies at the same time. In such "two-site" or "sandwich" assays, the anti¬ genic substance has two antibodies bound to its surface at different locations. In a typical "forward" sandwich assay, an antibody bound to a solid phase is first con- tacted with the sample being tested to form a solid phase antibody:antigen complex. After incubation, the solid support is washed to remove the residual sample, including unreacted antigen, if any. The complex is then reacted with a solution containing a known amount of labeled anti¬ body. After a second incubation to permit the labeled antibody to complex with the antigen bound to the solid support through the unlabeled antibody, the solid support is washed to remove unreacted labeled antibody. The assay can be used as a simple "yes/no" assay to determine whe¬ ther the antigen is present. Quantitative determinations can be made by comparing the measure of labeled antibody with that of calibrated samples containing known quanti¬ ties of antigen. "Simultaneous" and "reverse" sandwich assays are also known in the art. A simultaneous assay involves a single incubation step, both the labeled and unlabeled antibodies being added at the same time. A reverse assay involves the addition of labeled antibody followed by addition of unlabeled antibody bound to a suitable solid support. The sandwich technique can also be used to assay antibodies rather than antigens. Such an assay uses as a first receptor an antigen coupled to a solid phase. The antibodies being tested are first bound to the solid phase-coupled antigen. The solid phase is then washed, and then labeled anti-antibody (second receptor) is added. The radioallergosorbent technique (RAST) is a method for the determination of antigen-specific IgE. The method uses a solid phase coupled antigen and an immunoabsorbent purified antibody labeled with a radioactive isotope. The method is used to detect reaginic antibodies against vari¬ ous antigens which elicit allergic reactions (allergens) . The reaginic antibodies react with allergen bound to a solid matrix. After washing of the solid phase, the allergen-bound reaginic antibodies are detected by their ability to bind labeled antibodies against IgE. A variant of RAST can be used for the determination of allergens. The allergen to be tested is incubated with the reaginic antibody. The mixture is then tested with RAST using the same allergen coupled to the solid matrix. The allergen in solution reacts with the reaginic antibodies and thus inhibits the binding of these antibodies to the solid phase-coupled allergen. Another assay method for the determination of IgE is the radioimmunosorbent technique ("RIST"). In this method, the solid support is sensitized with anti-IgE and increasing amounts of labeled IgE are added to determine the maximum amount of IgE that can bind. A quantity of labeled IgE equivalent to approximately 80% of the plateau binding is chosen. In the test experiments, this amount of labeled IgE is mixed with the serum containing the IgE to be tested. The test IgE competes with the labeled IgE. The more IgE present in the test serum the less the amount of labeled IgE that binds. Thus, by producing a standard curve the amount of IgE in a sample can be determined. The above immunoassay methods can be applied to the assay of many different biologically active substances. Among such substances are haptens, hormones, gamma globu¬ lin, allergens, viruses, virus subunits, bacteria, toxins such as those associated with tetanus and animal venom, and many drugs. Similar techniques can be used in non- immunological systems with, for example, specific binding proteins. Although some of the immunoassay methods described above utilize radioactive labels, those skilled in the art will appreciate that the assays can be adapted to use an alternate label, for example, a fluorophore. If the properties of the label are not altered by binding, for example, as in a radioimmunoassay, a separa- tion step is required to separate "free" from "bound" labeled target analyte. Such assays, which require a separation step, are called "heterogeneous" assays. If the properties of the label are altered in some way when it is bound, no separation step is required, and the immunoassay is termed "homogeneous." The measurement of target analytes in biological fluids, such as serum, plasma and whole blood, requires immunoassay methods which are both specific and sensitive. Both the specificity and sensitivity of an immunoassay depend on the characteristics of the binding interaction between the target analyte and the receptor involved. For example, the reaction must be specific for the analyte to be measured and the receptor used should not bind to any other structurally related compounds. In addition, by choosing a receptor with a high affinity for the target analyte, the sensitivity can be increased. The label used to monitor the assay affects the sensitivity of an immunoassay. Labels currently used for immunoassay of target analytes in biological fluids include radioisotopes (radioimmunoassay, RIA) , enzymes (enzyme immunoassay, EIA) , fluorescent labels (fluores- cence immunoassay, * FIA) , and chemiluminescent labels (chemiluminescent immunoassay, CIA) . RIAs are sufficiently sensitive for use in detection in low concentrations of analytes because of their low background. They are disadvantageous in that they are heterogeneous, thus requiring a separation step before measurement of the bound and/or free portions of labelled target analyte. RIAs involve the inconvenience and haz¬ ards associated with the handling and disposing of radio¬ isotopes. In addition, they are labor intensive and have a short shelf life due to the half-lives of radiolabels and to chemical damage produced by the emitted radiation. EIAs have the advantage of increased signal over background, longer shelf life, lack of radiation hazards, and homogeneity. They are disadvantageous in that, because they involve enzyme kinetic reactions, they are affected by the time of the kinetic measurements, as well as by variations in temperature, pH and ionic strength. The temperature of the enzyme incubation is particularly critical, and variations of more than 0.5°C can signifi- cantly affect assay results. Thus, drifts in standard curve may result from temperature fluctuation and incon¬ sistencies in sample handling. ' Enzyme activity may also be affected by constituents in biological samples, such as plasma constituents. See generally Strong, J.E. and Altman, R.E., "Enzyme Immunoassay: Application to Thera¬ peutic Drug Measurement," in P. Moyer et al. , Applied Therapeutic Drug Monitoring. American Association of Clinical Chemistry (1984) . Chemiluminescent immunoassays (CIAs) offer a fairly high degree of sensitivity (picomole per liter range) but lack specificity in some instances. CIAs are disadvanta- geous because they are heterogeneous, require expensive reagents, and are expensive to automate. See generally Boeckx, R.L., "Luminescence: A New Analytical Tool for Therapeutic Drug Monitoring," in P. Moyer et al. , Applied Therapeutic Drug Monitoring, American Association of Clin- ical Chemistry (1984) . FIAs use fluorescent molecules as labels. Fluores¬ cent molecules (fluorophores) are molecules which absorb light at one wavelength and emit light at another wave¬ length. See Burd, J.F., "Fluoroimmunoassay — Application to Therapeutic Drug Measurement," in P. Moyer et. al. , App¬ lied Therapeutic Drug Monitoring, American Association of Clinical Chemistry (1984) . Typically, an excitation pulse of radiation is directed onto or into a sample, followed by fluorescence of the sample, and the detection of the fluorescence radiation. FIAs may be either heterogeneous or homogeneous. As noted above, homogeneous assays are usually simpler to perform and are thus, more amenable to automation. How¬ ever, previously known homogeneous FIAs are less sensitive than heterogeneous FIAs because high background can limit sensitivity. The heterogeneous FIA procedures can detect smaller amounts of analyte than present homogenous FIAs, but only because the separation and washing steps in the assays serve to eliminate background interference from biological substances. In solid phase fluorescent assays the solid support can limit sensitivity at the wavelengths of presently used fluors. In many cases the support itself will fluoresce at wavelengths of commonly used fluors such as fluorescein (493 nm) . FIAs also offer the advantage of using stable reagents. Another assay method uses enzyme-enhanced fluores- cence technology which combines microparticle capture and antigen-antibody reaction with an enzyme rate reaction using a fluorescent enzyme substrate. The rate reaction is monitored by steady state fluorometric measurement. In an enzyme-enhanced fluorescence assay, the analyte in question is "captured" by an antibody bound to a solid phase and the solid phase is washed. An enzyme is then bound to the captured analyte using an enzyme-anti analyte conjugate. Excess reactants are washed away and the amount of enzyme is measured by the addition of a non- fluorescent substrate. As the enzymatic reaction pro¬ ceeds, the non-fluorescent substrate is converted to the fluorescent product. For example, an alkaline phospha- tase-labeled antibody can be used to catalyze the hydro¬ lysis of 4-methylumbelliferyl phosphate substrate to the fluorescent product methylumbelliferone. Thus, the rate at which the fluorescent product is generated is directly proportional to the concentration of analyte in the test solution. Enzyme-enhanced fluorescence assays, like EIAs, have the disadvantages associated with enzymes. As discussed above, fluorescence is a phenomenon exhibited by certain substances, which causes them to emit light, usually in the visible range, when radiated by another light source. This is not reflection, but crea¬ tion of new light. Current commercially available assay methods use fluorescein, which emits green light when radiated by a light source containing blue light. In addition to fluorescing, fluorescein (and other fluorophores) emit polarized light. That is, the light emitted has the same direction of polarization as the incident polarized light, if the fluorescein molecule is held fixed wit its transition moment parallel to the electric field of the excitation. The amount of polariza- tion in the emission can be defined in terms of the inten¬ sity of the horizontally and vertically polarized light, as follows: P = (Iv - Ih)/(Iv + Ih) (1) where Iv = intensity of vertically polarized emission Ih = intensity of horizontally polarized emission The maximum, or limiting value of polarization, for fixed, randomly oriented molecules is 0.5 (Po) . A second equation (the Perrin equation) defines polarization in terms of physical parameters and Po: 1/P - 1/3 = (1/Po - 1/3) (1 + 3t/r) (2) where t = fluorescence lifetime, a constant r = rotational relaxation time Rotation relaxation is further defined for spherical molecules as r = 3nV/RT (3) where R = gas constant T = temperature, °K n = solution viscosity V = volume of molecule The rotational relaxation time is a measure of the rate at which a molecule will rotate when free in a solu¬ tion. Note that the rotational relaxation time will typically be dependent primarily on the molecular volume and shape, since solution viscosity and temperature will be essentially constant in a normal assay. Thus, rota¬ tional relaxation time, and consequently, polarization, are affected only by the hydrodynamic properties of the molecule. The smaller a molecule is, the smaller its rotational relaxation time, and the faster it rotates (e.g., r = 1 nsec for fluorescein, 100 nsec for large antibody complexes) . For a constant, small, fluorescence lifetime (4 nsec for fluorescein) , a small molecule retains little of the original polarization when irradi- ated by polarized light, because the molecule rotates rapidly and then fluoresces. On the other hand, a large molecule rotates slowly and for the same fluorescence lifetime, still retains a large degree of the original polarization when it fluoresces. This dependency of polarization on molecular size can be used to determine the presence or amount of drug. Using a fluorescent polarizing probe in a competitive binding immunoassay provides a type of FIA called a fluor¬ escence polarization immunoassay (FPIA) . In this type of assay, the smaller the molecule is, the smaller its rota¬ tional relaxation time and the faster it rotates. Typi¬ cally, antibody molecules are much larger than drug or drug-probe molecules. For example, r = 1 nsec for fluorescein and 57 nsec for gamma globulin. When there is a large amount of drug present, there are very few binding sites available for the drug-probe. As a result, most of the probe (fluorescein) is in the form of small drug-probe molecules. As these molecules rotate randomly and rapidly, a low polarization value results. When there is a small amount of drug present, much of the drug-probe is bound to the large antibody molecules. These molecules rotate slowly, so the emitted light will be highly polarized. The relationship between polarization and drug con- centration can be determined by creating a standard, or calibration, curve. This is done by running an assay using a range of known drug concentrations, from the lowest to highest expected concentrations, and plotting the resulting values of polarization. Thereafter, for a given value of polarization, the drug concentration can be determined from the standard curve. One advantage of the polarization technique is the elimination of a step to separate unbound probe. Although the unbound tracer is not physically eliminated from the samples in FPIA, its contribution is readily assessed by the. polarization. Another advantage in the FPIA technique is lack of dependence on intensity. In equation (1) above for cal¬ culating polarization using intensity, the ratio makes the polarization value unitless, or independent of variations in the intensity. Unlike most assays using a light mea¬ surement, in which it is the intensity of the light that is correlated to drug concentration (so any variations in source light intensity will directly affect the sensitiv¬ ity of the assay) , the sensitivity of FPIAs is independent of'intensity variations. Conventional FPIAs require sepa¬ rate measurements of both blank and sample. Theoretically, fluorometry is capable of being the most sensitive of all analytic tools as it is possible to detect single photon events. A problem which has plagued fluorescence immunoassays has been discriminating the fluorescent signal of interest from background radiation. The intensity of signal from background radiation may be up to 10,000 times larger than the intensity of the fluorescent signal of interest. The problem of background detection is particularly pronounced in assay of biological samples. Many of the current fluorescence assays use the fluorescent molecule, fluorescein. Fluorescein has an excitation maximum of 493 nm, and there are numerous substances in biological fluids with overlapping excitation and emission similar to fluor¬ escein. For example, in the analysis of blood plasma, the presence of a naturally occurring fluorescable material, biliverdin, causes substantial background radiation. Such compounds are highly fluorescent and contribute signifi- cant background signals which interfere with the label's signal, thus limiting -the sensitivity of assays using fluorescein labels. Earlier attempts to overcome the problem of back¬ ground radiation have met with limited success. One technique for overcoming the problem involves discrimi¬ nating against background radiation on the basis of wavelength. Filters have been used to reject detected radiation at all but a narrowly defined wavelength band. This technique has been less than successful principally because the background radiation may also be at the same wavelength as the desired fluorescence signal, accord- ingly, still be passed through the filter and detected. It has been recognized that for analysis of biologi¬ cal fluids, it would be desirable to use a dye or label which is excitable at radiations of wavelengths of greater than background radiation. However, even though the back- ground fluorescence of serum falls off at wavelengths approaching 600 nm, significant decrease does not occur until 650 nm or greater. Previous attempts to create dyes of such wavelengths have been unsuccessful. See, e.g. , Rotenberg, H. and Margarfit, R. , Biochem. Journal.229:197 (1985) ; and D. .R. Laurence, Biochem. Journal 51:168 (1952) . A second technique attempting to * discriminate the desired fluorescent signal from the background is the so called time gating approach. Here, the fluorescent signal is observed in a short time window after the excitation. The time window may be varied both in its length and in its starting time. Through the use of the variable time window, the detected radiation may be observed at the maximal time for detection sensitivity. Historically, this technique has used a fluorophore of very long decay time (such as 1,000 nanoseconds) to allow the background fluorescence to substantially decay before detection of the fluorescent signal of interest. Generally however, long decay time fluorophores require longer times for overall analysis. Due to the long decay time, the light source cannot be pulsed rapidly to collect: data, thus requiring additional time for final analysis. Historically, there have been two excitation pulse formats for transient state fluorescent analysis. One format utilizes a single, relatively high power pulse which excites the fluorophore. The transient state is typically monitored by a high speed photomultiplier tube by monitoring the analog signal representative of current as a function of time. Single pulse systems require sufficiently high power to excite a large number of fluorescent molecules to make detection reliable. The other principal format for transient state fluorescent analysis is a digital format which utilizes repetitive excitation pulses. Ordinarily, pulses of relatively short, typically nanosecond duration, light with power in the microwatt range are repetitively supplied to the sam- pie at rates varying from 1 to 10,000 Hz. Ordinarily, the excitation source is a lamp, such as a Xenon-lamp. Fre¬ quently, the decay curve is measured digitally by deter¬ mining the time to receipt of a photon. One commercially available system uses repetitive pulses (such as at 5,000 Hz) and pulses the photomultiplier tube at increasingly longer times after the flash in order to obtain a time dependent intensity signal. Detection in such systems has proved to be very time consuming and insensitive. A single analysis can take on the order of one hour, even at relatively high fluorescable dye concentrations (e.g. , 10 "6 M) . Recently, significant advances have been made in the area of fluorescable dyes. In one aspect, dyes being excitable by longer wavelength radiation, such as in the red and infrared wavelengths, are now available. These dyes are described in two commonly assigned patent applications: Arrhenius, U.S. Patent Application Serial No. 701,449, filed May 15, 1991, entitled, "Fluorescent Marker Components and Fluorescent Probes," (which is a continuation-in-part of U.S. Patent Application No. 523,601, filed May 15, 1990), and Dandliker and Hsu, U.S. Patent Application Serial. No. 201,465, filed May 15, 1991, entitled "Fluorescent Dyes Free of Aggregation and Serum Binding" (which is a continuation-in-part of U.S. Patent Application Serial No. 524,212, filed May 15, 1990) . These applications are incorporated herein by this reference. Further significant advancements have been made in increasing sensitivity through data collection and analy¬ sis techniques. As disclosed in Dandliker et al. , U.S. Patent No. 4,877,965, entitled "Fluorometer, " which is incorporated herein by this reference, time gating tech¬ niques are used in conjunction with data collection and analysis techniques to obtain an improved signal relative to the background. Generally, the '965 Patent considers the detected intensity as a function of time to be com- posed of signals from various sources, including the desired signal source, and various undesired background sources. Optimization of the desired signal is achieved through data collection and analysis techniques. Further significant advancements have been made in the ability to measure relevant materials in immunoassays. For example, using the technique described in Dandliker, et al. , U.S. Patent Application Serial No. 490,770, filed March 6, 1990, entitled "Transient State Luminescence Assays," (which is a continuation-in-part of U.S. Patent Application Serial No. 365,420, filed June 13, 1989) incorporated herein by this reference, allows the bound and free form of materials in a homogeneous assay to be determined. Generally, the technique requires measurement of the time-dependent decay of the intensity of parallel and perpendicular polarization components. By measuring the time-dependent decay of various polarization states, it is possible to determine the bound and free forms of materials such as haptens, peptides, or small proteins in a homogeneous analysis format. Significantly, no separa- tion of the bound and free materials is required. Despite the significant and promising improvements made in the field of fluorescable dyes, and in the data analysis aspects, the actual methods and apparatus for achieving and detecting fluorescence have heretofore remained relatively unchanged. Utilizing even the most sensitive and best equipment, analysis can take an hour or more, even at high concentrations of materials. When fluorometry is used for immunoassay in a clinical context, time for analysis and proper diagnosis can be absolutely critical. Patient survival can depend on accurate, timely analysis. Additionally, rapid testing would permit retests of patients without having them wait significant periods of time, resulting in more rapid and accurate diagnosis. As to sensitivity, it is extremely desirable to be able to detect minute amounts of fluorescable mater¬ ial. However, as the amount of fluorescable material in a sample decreases, the ratio of the signal increases. Further, since the time for analysis depends on the amount of fluorescent radiation received from the detector, low concentrations generally require substantially more time to analyze. Heretofore, the time required for analysis has been prohibitively high. Known methods and apparatus for FIAs have failed to provide rapid and accurate diagnosis and analysis of samples. This has been so despite the clear and known desirability of the use of FIAs. For example, the drug digoxin, which is used to treat congestive heart failure, has a narrow therapeutic range (i.e. , serum levels of 0.5 to 2.5 ng/ml and is generally toxic at concentrations greater than 2.1 ng/ml. Present assays using fluorescence-based methodologies require an extrac - ing process to remove interfering substances, such as proteins, in order to detect digoxin at its therapeutic levels. This additional extraction step increases the time, cost and equipment needed to perform the assay. From the above discussion it can be seen that, although many different types of immunoassays currently exist, none is satisfactory for measuring small quantities of target analytes in biological fluids such as serum, plasma and, especially, whole blood. Accordingly, an object of the present invention is to provide improved processes for assay of antigenic substances. More speci¬ fically, the present invention provides fluorescence assays which allow the detection of low levels of anti¬ genic substances in biological samples such as serum, plasma and whole blood. The present invention also pro¬ vides homogeneous fluorescence assays which allow rapid and accurate determination of low levels of antigenic substances in biological samples. Summary of the Invention The present invention is directed to methods for determining the presence or amount of a target analyte in a sample by using, as a label for the target analyte or a receptor which is capable of specifically recognizing the target analyte, a fluorophore moiety comprising a lumi¬ nescent substantially planar molecular structure coupled to two stabilizing polyoxyhydrocarbyl moieties, one located on either side of the planar molecular structure. By "target analyte" is meant the antigenic substance being assayed, for example an antigen. By "receptor" is meant a molecule or molecular component capable of specifically recognizing the target analyte. For example, an antibody may be a receptor for an antigen. Use of such detectable labels or marker components in immunoassays is advantageous in that these labels have substantially the same intensities of parallel and perpen¬ dicular components of transient state fluorescence emis¬ sion in the presence and absence of biological fluids such as serum. Thus, assay methods using these labels are capable of detecting low concentrations of target analyte in biological fluids. The methods of the present invention are particularly suitable for use with the improved fluorescence detection system described in commonly assigned U.S. Patent Applica- tion entitled "Fluorometer Detection System, " Lyon & Lyon Docket No. 195/129, filed concurrently herewith. In one aspect, the present invention is directed toward competitive inhibition assay procedures utilizing particular labels. In this aspect, the present invention is directed to a method of determining the presence or amount of a target analyte by contacting a sample sus¬ pected of containing the target analyte with a known quantity of added target analyte or analog thereof linked to a fluorescent probe which includes a detectably labeled marker component made up of a fluorophore moiety which includes a luminescent substantially planar molecular structure coupled to two solubilizing polyoxyhydrocarbyl moieties, one located on either side of the planar mole- cular- structure; contacting the sample with a receptor capable of specifically recognizing the target ligand; and determining either the amount of fluorescent probe bound to receptor or free fluorescent probe. The amount of bound or free fluorescent probe in the unknown samples may be compared with blank samples and samples containing known amounts of target analyte. In a preferred embodiment, the resultant mixture of sample, fluorescent probe and receptor is diluted before measurement of the amount of bound and/or free fluorescent probe. The dilution step allows for greater sensitivity of the assay. Particularly preferred are dilutions of 2-fold to 100-fold, preferably about 7-fold to about 50-fold, and more preferably about 35-fold. In one aspect, the present invention provides an improvement in immunoassay procedures which utilize a label for either the target analyte (or analog thereof) or the receptor. The improvement is the use of a fluorophore moiety comprising a luminescent substantially planar mole¬ cular structure coupled to two solubilizing polyoxyhydro- carbyl moieties, one located on either side of the planar molecular structure. Assays using this type of label are advantageous in that they are free of serum binding and aggregation and are therefore, especially suitable for testing biological samples such as serum, plasma, whole blood and urine. In another aspect, the present invention provides a method for performing a "sandwich" or "two-site" immuno¬ assay comprising the steps of: (a) contacting a sample suspected of con¬ taining a target analyte with a first receptor capable of specifically recognizing said target analyte to form a complex of said target analyte and said first receptor, said first receptor being labeled with a fluorescent probe which comprises a fluorophore moiety comprising a luminescent substantially planar molecular structure coupled to two solubilized polyoxy- hydrocarbyl moieties, one located on either side of the planar molecular structure; (b) contacting the complex with a second receptor capable of specifically recognizing said target analyte to, said second receptor being bound to a solid carrier, to form a com¬ plex of said first labeled receptor, said target analyte and said second receptor bound to said solid carrier; and (c) measuring either the amount of labeled first receptor associated with said solid car¬ rier or the amount of unreacted labeled first receptor. A sandwich-type assay may be either a heterogeneous assay or a homogeneous assay. If it is heterogeneous, it may incorporate the additional step of separating the solid carrier from the unreacted labeled first receptor. Homogeneous assays are generally preferred because they are more rapid. In another embodiment, the assay may incorporate the additional step of relating the amount of labeled first receptor measured in the unknown sample to the amount of labeled first receptor measured in a control sample free of said target analyte, or to the amount of labeled first receptor measured in samples containing known quantities of target analyte. In another aspect, the present invention provides a method for a simultaneous sandwich-type assay comprising a method for determining the presence or amount of a target analyte in a sample comprising the steps of : (a) simultaneously contacting a sample suspected of containing a target analyte with first and second receptors capable of specifi¬ cally recognizing said target analyte, said first receptor being labeled with a fluorescent probe which comprises a fluorophore moiety com- prising a luminescent substantially planar mole¬ cular structure coupled to two solubilized poly- oxyhydrocarbyl moieties, one located on either side of the planar molecular structure, and said second receptor being bound to a solid carrier, to form a complex of said first receptor, said target analyte, and said second receptor; and (b) measuring either the amount of labeled first receptor associated with said solid car¬ rier or the amount of unreacted labeled first receptor. In another aspect, the present invention provides a method for a simultaneous sandwich-type assay comprising a method further comprising the step of relating the amount of labeled first receptor measured to the amount of labeled first receptor measured for a control sample free of said target analyte, or relating to the amount of labeled first receptor measured with the amount of labeled first receptor measured in samples containing known amounts of target analyte. In another aspect, the present invention provides a sandwich-type fluorescence immunoassay method for measure¬ ment of a target analyte which is capable of recognizing two different receptors independently without mutual interference. The method utilizes two receptors, each of which is labeled with a different dye. For example, one receptor is labeled with a first dye having absorption and emission maxima of 680 nm and 690 nm, respectively, and the other receptor is labeled with a second dye having absorption and emission maxima of 695 and 705 nm, respec¬ tively. Detection and quantitation of the analyte can be made using either steady state or transient state measure- ments. In either case, for the example given, excitation would be at 680 nm and detection would be at 705 nm. This type of assay is based on energy transfer and is advan¬ tageous in that it is homogeneous. In preferred embodiments the present invention is directed to immunoassay of biological fluids, including serum, plasma, whole blood and urine. Preferably, red blood cells in whole blood are lysed prior to assay of whole blood samples. Preferred methods of lysing red blood cells include addition of stearyl-lysolecithin, palmitoyl-lysolecithin and myristoyl lysolecithin. Depending on the type of immunoassay used, the target analyte may be an antigen, a hapten or an antibody; and the receptor may be an antigen or antibody. The antibody may be polyclonal or monoclonal. Preferably, the antibody is a monoclonal antibody. Monoclonal antibodies useful in the present invention may be obtained by the Kohler & Milstein method reported in Nature 256:495-497 (1975) . Alternatively, they may be produced by recombinant methods. Science 246:1275-1281 (1989) . In one embodiment, the target analyte is a drug or a metabolite of a drug. The drug may be a steroid, hormone, antiasthmatic, antineoplastic, antiarrhythmic, anticonvul- sant, antiarthritic, antidepressant, or cardiac glycoside. Examples of such drugs include digoxin, digitoxin, theo- phylline, phenobarbital, thyroxine, N-acetylprocainamide , primidone, amikacin, gentamicin, netilmicin, tobramycin, carbamazepine, ethosuximide, valproic acid, disopyramide, lidocaine, procainamide, quinidine, ethotrexate, ami- triptyline, mortriptyline, imipramine, desipramine, van- comycin, and cyclosporine. In a preferred embodiment, the drug is digoxin. In another embodiment, the target analyte is a pep¬ tide, for example, a peptide hormone such as luteinizing hormone, follicle stimulating hormone, human choriogonado- tropin, thyroid stimulating hormone, angiotensin I, angio- tensin II, prolactin or insulin. The peptide may also be a tumor marker such as carcinoembryonic antigen. Or, the peptide may be a virus or portion thereof, for example, rubella virus or a portion thereof. The methods of the present invention provide ways of measuring target analytes in concentrations of from about 1 x 10 "5 M/L to about 1 x 10 "13 M/L, and particularly in the concentration range of from about 1 x 10" 9 M/L to about 1 x 10 "12 M/L. For measurement of drugs and their metabolites, the present methods allow measurement in the range from about 5 x 10" 9 M/L to about 5 x 10" 12 M/L, and particularly, concentrations of from about 1 x 10" 10 M/L to about 5 x 10 "10 M/L. For measurement of peptides, the present methods allow measurement in the range of from about 1 x 10 "11 M/L to about 1 x 10 "12 M/L. The measurement of amount of fluorescent probe — bound or free or both — can be determined by measuring steady-state fluorescence or by measuring transient state fluorescence. In a preferred embodiment, the wavelength of light measured is greater than about 500 nm, preferably greater than about 650 nm, and more preferably greater than about 680 nm or 690 nm. Because the transient state detection system utilizes a laser diode, it is necessary for the dyes to have excitation maxima matched to the diode output wavelengths. Dyes have been made available to match other commercially available laser diodes have output wavelengths of 680, 690, 720, 750, or 780 nm. Thus, the wavelength of the light measured may be greater than about 680 nm, 690 nm, 720 nm, 750 nm or 780 nm. The further into the red region of the spectrum one moves, i.e. , the greater the wavelength, the greater signal enrichment there is over background. In a preferred embodiment, detection and quantitation is performed using transient state measurement. Transient state energy transfer offers improved measurements due to optimization of the wavelengths of absorption and emis¬ sion, as well as due to optimization of the decay times of the first and second dyes. Such optimization allows removal of Rayleigh and Raman scattering, and achieving the best compromise between efficiency of transfer and the undesired direct excitation of the second dye by the first dye. In one aspect, the present invention is directed to immunoassays using detectably labelled marker components which comprise a fluorophore moiety which comprises a substantially planar macrocyclic multidentate ligand coordinated to a central atom and two solubilizing poly¬ oxyhydrocarbyl moieties, one linked on either side of the plane of the multidentate ligand to the central atom. In one preferred aspect, the present invention is directed to immunoassays using a marker component compris¬ ing a fluorophore moiety which comprises a substantially planar multidentate macrocyclic ligand coordinated to a central atom capable of coordinating with two axial lig¬ ands which are coordinated to the central atom on either side of the macrocyclic ligand. Marker components used in the immunoassays of the present invention comprise a macrocyclic multidentate ligand having two solubilizing polyoxyhydrocarbyl moieties one located on either side of the plane of the multiden¬ tate ligand exhibit no detectable non-specific binding to serum components, and exhibit no detectable solvent sensi¬ tivity. These marker components also exhibit enhanced decay times which approach their natural (fluorescent) lifetimes. Preferred are fluorophores which produce fluorescent light efficiently, i.e. , which are characterized by high absorbitivity at the appropriate wavelength and high fluorescence quantum yields. For certain applications, preferred fluorophores have measured fluorescence decay times on the order of at least 2 nanoseconds and exhibit a high degree of fluorescence polarization. Preferred solubilizing polyoxyhydrocarbyl moieties include water soluble carbohydrates such as glucose, sucrose, maltotriose, and the like; water soluble car¬ bohydrate derivatives such as gluconic acid and mannitol and oligo saccharides; and water soluble polymers such as polyvinylpyrrolidone, poly(vinylalcohol) , poly(ethyleni- mine) , polyacrylic acid, polyacrylamide, ethylene oxide copolymers such as Pluronic (a propylene oxide copolymer, available from BASF) and Tetronic (BASF) polyol surfac¬ tants; and polyethers, including water soluble polyoxy- alkylene polymers, particularly poly(ethylene glycol) ("PEG") and poly(ethylene glycol) derivatives such as poly(ethylene glycol) methyl ether, poly(ethylene glycol) silicon derived ethers and the like. In one aspect, the present invention is directed to immunoassays using marker components comprising a fluoro¬ phore moiety which comprises a substantially planar, mul- tidentate macrocyclic ligand coordinated to a central atom capable of coordinating with two axial ligands and two polyoxyhydrocarbyl moieties which are attached as axial ligands to the central atom. Suitable central atoms are those to which may coordinate two axial ligands and which are not of high enough atomic number to cause extensive fluorescence quenching by transition to the triplet state. Preferred elements for the central atom include silicon, germanium, phosphorus, and tin, especially preferred are silicon and germanium. Depending on the type of immunoassay, these marker components may be used as labels for labelling an analyte, antigen, antibody or other molecule. These marker compo- nents may be optionally functionalized so as to include a linker arm which allows the marker component to be linked to the analyte, antigen, antibody or other molecule. A variety of linker arms which may be suited to this pur- pose. The marker component is linked to the analyte, antigen, antibody or other molecule using conventional techniques. The present invention is also directed to the use of divalent peptide derivatives as analogs for large mole- cules in immunoassays. Preferably, a divalent hapten consisting of two epitopes of the same specificity con¬ nected by a linker about 10 nm long is used to bind to a single antibody molecule, requiring approximately 26 residues. The present invention also includes assay methods of involving cellular receptors located on the plasma mem¬ brane or isolated from cytosols and synthetic ligand binders obtained by molecular imprinting. Accordingly, it is a principal object of this inven- tion to provide improved FIAs with greatly enhanced sen¬ sitivity. It is yet another object of this invention to provide FIA methods which allow rapid and accurate deter¬ minations, often within a matter of minutes. It is an object of this invention to provide FIA methods which are capable of measuring extremely low concentrations of fluorescable material. It is an object of this invention to provide FIA methods useful for the clinical setting in that they are rapid and accurate, of relatively low cost and capable of use with unmodified biological samples, such as whole blood. It is a further object of this invention to provide FIA methods particularly adapted to exploit the improved fluorescence detection system, described in U.S. Patent Application entitled "Fluorometer Detection System, " Lyon 5c Lyon Docket No. 195/129, referenced above. It is a further object of this invention to provide homogeneous "mix and read" digoxin assay methods which can be used to determine the level of digoxin in serum, plasma or whole blood. It is a further object of this invention to provide an assay for peptides, for example, for a rubella virus or a portion thereof. The present invention also provides particular fluor¬ escent probes for use in immunoassays, for instance, see Examples 3 and 11-18 below. Definitions: As used herein, the following terms have the follow¬ ing meanings unless expressly stated to the contrary: The term "target analyte" refers to the compound or compound to be measured in an assay which may be any compound for which a receptor naturally exists or can be prepared which is mono- or polyepitopic, antigenic or haptenic, a single or plurality of compounds which share at least one common epitopic site or a receptor. By "analog" of a target analyte is meant a compound or com¬ pounds capable of competing with the target analyte for binding to a receptor. The term "axial ligand" refers to a substituent which, together with a macrocyclic ligand, forms a coordination complex with a central atom. The axial ligand lies normal to the plane described by the macro¬ cyclic ligand. The term "fluorescent probe" refers to a marker component comprising a fluorophore moiety which is bonded to or coordinates either directly or via a linker arm to an analyte, antigen, hapten, antibody or other molecule which is used in an assay, such as a fluoroimmunoassay to determine the presence of and/or quantitate a substance of interest. The term "solvent sensitivity" refers to changes in the fluorescence behavior of a molecule depending on the solvent system in use, most notably referring to differ¬ ences in fluorescence behavior in aqueous solution in comparison with organic solvents (such as DMF) . ' Many fluorophores which exhibit high fluorescence intensity in organic solvents such as DMF show substantially decreased fluorescence intensity in aqueous solution. Fluorescence intensity is related to sample concen¬ tration and the intensity of the exciting radiation. The fluorescence intensity of a particular dye can be corre- lated to its characteristic light absorptivity (extinction coefficient) and fluorescence quantum efficiency, as well as environmental factors. The term "specific binding pair" refers to two dif¬ ferent molecules (or compositions) wherein one of the molecules has an area on the surface or in a cavity which specifically recognizes and binds to a particular spatial and polar organization of the other molecule or molecular complex involving other molecules. The term "binding partner" refers to a molecule or molecular complex which is capable of specifically recog¬ nizing or being recognized by a particular molecule or molecular complex. The term "bound" refers to the condition in which a binding interaction has been formed between a molecule and its specific binding partner. The term "decay time" is the time which must elapse in order for the concentration of excited molecules to decrease from its initial concentration to 1/e of that value. The term "receptor" refers to a molecule or molecular complex which is capable of specifically recognizing or being recognized by a target analyte or analog thereof. Brief Description of the Drawings Fig. 1 depicts an HPLC analysis of crude caged dicar- boxy silicon phthalocyanine dye preparation. Fig. 2 shows the absorbance of caged dicarboxy sili¬ con phthalocyanine dye in various solvents. Fig. 3 describes the Diatron Analog System. Fig. 4 depicts the decay time for caged dicarboxy silicon phthalocyanine dye. Fig. 5 shows serum interactions of purified caged dicarboxy silicon phthalocyanine dye. Fig. 6 depicts the absorbance spectrum of caged dicarboxy silicon phthalocyanine dye-C12 linker. Fig. 7 depicts the polarization of caged dicarboxy silicon phthalocyanine dye-C12 linker at 680 nm. Fig. 8 depicts the polarization of caged dicarboxy silicon phthalocyanine dye-C12 linker at 690 nm. Fig. 9 depicts an HPLC Chromatograph of caged dicar- boxy silicon phthalocyanine digoxin probe. Fig. 10 depicts the structure of caged dicarboxy silicon phthalocyanine digoxin probe. Fig. 11 shows the absorbance spectrum of caged dicarboxy silicon phthalocyanine digoxin probe in methanol. Fig. 12 shows the absorbance spectrum of caged dicarboxy silicon phthalocyanine digoxin probe in FPIA buffer. Fig. 13 shows the decay time for caged dicarboxy silicon phthalocyanine digoxin probe. Fig. 14 shows the linearity of intensity for caged dicarboxy silicon phthalocyanine digoxin probe. Fig. 15 shows serum/urine interactions for caged dicarboxy silicon phthalocyanine digoxin probe. Fig. 16 depicts a comparison of TDx ® and FAST-60 calibration curves. Fig. 17 depicts the correlation of digoxin samples assayed by TDx ® and FAST-60. Fig. 18 depicts the effect of dilution jump on non- specific binding. Fig. 19 depicts a digoxin probe-serum calibration curve. Fig. 20 depicts a calibration curve for a high sensi¬ tivity digoxin assay. Fig. 21 describes the FAST-60 digoxin assay procedure. Fig. 22 depicts digoxin correlation — TDx ® Serum vs. FAST-60 Whole Blood. Fig. 23 depicts digoxin correlation — Stratus ® Serum vs. FAST-60 Whole Blood. Fig. 24 depicts digoxin correlation — ' FAST-60 Serum vs. FAST-60 Whole Blood. Fig. 25 depicts digoxin correlation — TDx ® Serum vs. FAST-60 Serum. Fig. 26 depicts digoxin correlation — Stratus ® Serum vs. FAST-60 Serum. Fig. 27 depicts the structure of caged dicarboxy silicon phthalocyanine digitoxin probe. Fig. 28 depicts the structure of caged dicarboxy silicon phthalocyanine theophylline probe. Fig. 29 depicts the structure of caged dicarboxy silicon phthalocyanine phenobarbital probe. Fig. 30 depicts the structure of caged dicarboxy silicon phthalocyanine thyroxine probe. Fig. 31 depicts the structure of caged dicarboxy silicon phthalocyanine n-acetylprocainamide probe. Fig. 32 depicts the structure of caged dicarboxy silicon phthalocyanine primidone probe. Fig. 33 depicts the structure of caged dicarboxy silicon phthalocyanine phenytoin probe. Fig. 34 depicts a rubella antibody calibration curve for a sandwich assay. Fig. 35 depicts a rubella peptide calibration curve for an inhibition assay. Fig. 36 depicts a rubella antibody calibration curve for direct polarization. Detailed Description of the Invention The present invention provides fluorescence immuno¬ assay methods which have dramatic increases in sensitivity over previous methods, which can be easily performed 5 because they require no separation step, and which can be used to detect and quantitate low levels of target analyte in biological samples such as serum, plasma, whole blood and urine. The FIAs of the present invention may be per¬ formed in small samples. For example, a digoxin assay may 10 be performed on a 20 μl sample of serum, plasma or whole blood, and the assay may be performed in about five min¬ utes. The ability to perform FIAs on whole blood samples is particularly significant because it allows assays to be performed at locations closer to the patient, such as 15 physicians' offices and emergency rooms. The capability of performing FIAs rapidly is important because, in a clinical context, patient survival can depend on accurate, timely results. The concept of sensitivity in fluorescence measure- 20 ments can be usefully quantified by specifying the con¬ centration of the fluorophore in question at which the fluorescence intensity from the fluorophore is equal to the intensity from the background. This manner of expressing sensitivity emphasizes the fact that the 25 sensitivity of fluorescence measurements is almost always determined by the ability to discriminate between "signal" and "background" and not by the absolute number of photons available from the "signal." The present invention provides methods for FIAs which 30 solve the problem with discriminating against background 4. radiation on the basis of wavelength. The probes used in the method of the invention have excitation (and emission) wavelengths greater than about 650 nm, preferably greater than 680 nm. This wavelength shift into the infra-red 35 range decreases background fluorescence, i.e., increases signal-to-background ratio. This decrease in background fluorescence allows the use of fluorophore at far lower concentrations than previously used in homogeneous FIAs. The probes used in the present assay methods have low dielectric constants, which applicants believe tend to increase the Van der Waal interactions and hydrogen bond¬ ing, thus accelerating the antigen/antibody reaction. In addition, applicants believe that these probes compete for the water of hydration, thus potentiating the antigen/ antibody reaction. In other words, the probes not only substantially decrease non-specific bindings to serum components, but applicants believe that they potentiate the immunochemical reaction. For fluorescence polarization assays, the present invention provides a further increase in sensitivity by measuring transient state fluorescence rather than the steady state signal. In the steady state mode the signal is constant over time enabling the determination of one experimental parameter, e.g. , the polarization or the anisotropy, both of which are related to molecular rotational motion. In the transient state mode the signals vary in a systematic way with time. This varia¬ tion represents a complex summation of the rates of decay and of molecular rotation as it changes from moment to moment in time. The increase in sensitivity from transient state measurements stems from two sources. First, that portion of the background due to Rayleigh and Raman scattering disappears in about 10 "15 sec and so is cleanly removed before the transient state measurements start. This portion of background is normally an important part of the total in steady state measurements. Above and beyond the removal of scattering, the tran¬ sient state measurements provide an additional powerful means to discriminate between the desired signal and the remaining fluorescence portion of the background. This discrimination rests upon the time dependence of the polarized components in the fluorescence decay and makes it possible to extract the desired signal only, simultane¬ ously on the basis of the rate of decay of the excited state and the rate of decay of the rotational distribution imprinted by the excitation. Thus, transient state methods allow signal to be distinguished from background in ways not possible with steady state information alone. In addition to these features, the probes exhibit a high degree of polarization, necessary for mix and read (homogeneous) fluorescence polarization assays. This increase in polarization translates into increased sensitivity. The methods of the present invention are particularly useful when used with a time-correlated transient state detection system, as described in commonly assigned Studholme, et. al.. U.S. Patent Application entitled "Fluorometer Detection System, " Lyon & Lyon Docket No..195/129, filed concurrently herewith. That system features transient detection along with detection of the time-dependent polarization of the sample. .The system uses a laser diode which can be modulated at very high frequencies, e.g.. 10 MHz rate, and exhibits high output power. Typically the laser "on" time is approximately 2-3 nanoseconds. Photons from the solution are detected using a photomultiplier tube (PMT) operating in a single photon counting mode. The photon event along with the relative time of the photon event as compared with the laser pulse time is determined. By storing the individual photon event times a histogram of frequency of photons as a function of time is generated. Data obtained in this manner can be analyzed as described in Dandliker et, al. , U.S. Patent No. 4,877,965, entitled "Fluorometer" or as described by Studholme, et al. , U.S. Patent Application entitled, "Fluorometer Detection System," Lyon & Lyon Docket No. 195/129, filed concurrently herewith. The methods of the present invention also include the use of divalent peptide derivatives as analogs for large molecules in immunoassays. Both polyclonal and monoclonal antibody molecules are divalent. Due to the "chelate effect, " the binding of a low molecular weight mimic or analog of a larger molecule will be stronger and dissoci- ation from the antibody will be slower if both antibody binding sites are utilized in the bonding. It is within the scope of the present invention to arrange the struc¬ ture of the peptide analog to have two identical sequences joined together by a linker of suitable length so as to place the two peptide sequences, in their normal config¬ uration in solution, in the most favorable position for reaction with the two sites on the same antibody molecule. Preferably, several such unspecific, divalent analogs are used as a cocktail, rather than combining more than one epitope in the same analog molecule. The latter arrangement would permit cross linking of perhaps many antibody molecules which might be preferable in solid phase assays in which the formation of chains and cycles could aid in adhering to a surface. Conversely, having two identical epitopes on the same analog molecule may "inhibit" polymerization by strongly favoring, by prox¬ imity factors, reaction with two sites on the same molecule. The use of divalent peptide derivatives as analogs for large molecules in immunoassays is preferred in solution, especially in conjunction with dilution jump, due to the tighter binding afforded by the "chelate effect, " resulting in an increase in the sensitivity of the immunoassay. Preferably, a divalent hapten consisting of two epitopes of the same specificity connected by a linker about 10 nm long is used to bind to a single antibody molecule. Taking into account the bond distances and angles for simple peptides (L. Pauling, The Nature of the Chemical Bond, Cornell University Press (1960) , p. 498) and assuming a length of 0.380 nm per amino acid residue, this would require approximately 26 residues for a 10 nm length. One approach for designing a divalent hapten with such a linker is to synthesize the epitope with a 13 resi- due linker terminating in a primary amino group. This peptide is then reacted with the bis (3-isocyanatopropyl- dimethylsilyl) derivative of dihydroxysilicon phthalocya¬ nine. The resulting structure has the phthalocyaninine moiety with two axial substituents, one on either side of the molecular plane, each consisting of a thirteen residue peptide linker leading to the peptide epitope. The mole¬ cular plane of the dye moiety is perpendicular to the direction of the linker. After combination of the two peptide epitopes with the two binding sites of the same antibody molecule the dye moiety may be located midway between the two arms of the Y-shaped antibody molecule. The polarization changes obtainable with this type of structure may not be as great as if the dye were linked through a peripheral rather than an .axial bond, and the absence of PEG may result in non-specific binding. How¬ ever, if the dye moiety is held close to the antibody surface between the two Fab fragments after binding, it may prove to be quite protected and rotate with the long¬ est rotational decay time of the antibody (since the molecular plane of the dye may lie parallel to the long axis of the antibody) . Alternatively, a divalent peptide hapten may be designed to utilize the PEG protected dye linked through a peripheral carboxyl to an amino group on the linker or on one of the peptide epitopes, e.g. , the linkage could be the e-amino group of a lysine residue located approxi¬ mately midway on an interconnecting chain between the two peptide epitopes. Immunoassays, a class of ligand binding assays, depend upon the strong and selective binding of some analyte of interest to antibody specific for that analyte. Other molecular structures that have similar strong and selective binding for such an analyte can serve equally well in designing an assay and such structures may have some inherent advantages over antibody. For example, molecules which may have desirable properties in this context include cellular receptors located on the plasma membrane or isolated from cytosols and synthetic ligand binders obtained by a process known as "molecular imprinting. " The sensitivity of a ligand binding assay depends upon the binding affinity of association constant (K) of the reaction between the analyte and the binding molecule. For classical cytosolic steroid hormone receptors these Ks are of the order of 10 9 M "1 . In recent work with molecular imprinting of synthetic polymers the binding constant for diazepam was found to be about 10 8 M "1 (Vlatakis et, al. , Nature 361: 645-647 (1993)). By contrast, the highest Ks for antibody binding are of the order of 10 12 M "1 for lig¬ ands such as fluorescein and digoxin. The magnitude of these Ks suggest that antibodies bind far more tightly than do receptors or molecular imprints. Binding processes are symmetrical and the observed K depends upon both the "receptor" and the "ligand" and the distinction between the two is made for convenience. Applicants believe that because relatively few Ks have been measured for receptors or molecular imprints, there is no reason that the binding by these molecules should not be potentially as tight as by anti¬ body. Molecular imprints also have the inherent advantage of being tailored for one specific molecule and the Ks can be improved by the proper placement of hydrophobic, polar and ionic groups in the binding sites. Moreover, because these molecules are synthetic, once the optimal structure is known large amounts should be readily obtainable. Thus, the present invention includes methods of involving cellular receptors located on the plasma mem¬ brane or isolated from cytosols and synthetic ligand binders obtained by molecular imprinting. I. Preferred Marker Components The following is a brief description of the preferred marker components to be used in the fluorescence immuno¬ assays of the present invention. A more complete discus- sion is found in commonly assigned U.S. Patent Applica¬ tions Serial Nos. 701,449 and 201,465, which, as noted above, have been incorporated herein by reference. A. Preferred Fluorophore Moieties Suitable fluorophore moieties comprise a luminescent substantially planar molecular structure. Preferred are fluorophore moieties in which the luminescent substan¬ tially planar molecular structure comprises a substan¬ tially planar macrocyclic multidentate ligand which coordinates a central atom which may coordinate with two axial ligands, one on either side of the macrocyclic ligand (i.e. having a trans orientation) . Preferred central atoms are elements which may form octahedral coordination complexes containing two ligands with a trans or axial orientation, on either side and perpendicular to the planar macrocyclic ligand. For use as fluorescent marker components in certain applications the central atom should not have too high atomic number (about 30 or less) so that fluorescence is not diminished through coupling interaction with orbitals of the central atom. Preferred multidentate ligands include nitrogen- containing macrocycles which have conjugated ring systems with pi-electrons. These macrocycles may be optionally substituted, including substitution on bridging carbons or on nitrogens. Suitable macrocycles include derivatives of porphyrins, azaporphyrins, corrins, sapphyrins and por- phycenes and other like macrocycles which contain elec¬ trons which are extensively delocalized. In view of the fact that they incorporate many of the above-noted char- acteristics, an especially preferred class of macrocycles comprise porphyrin derivatives, and azaporphyrin deriva- tives (porphyrin derivatives wherein at least one of the bridging carbons is replaced"by a nitrogen atom) . Azapor¬ phyrin derivatives include derivatives of mono-, di- and triazaporphyrin and porphyrazine. These macrocycles may optionally have fused aromatic rings. These azaporphyrin derivatives include phthalocyanine, benzotriazaporphyrin and naphthalocyanine and their derivatives. The prepara¬ tion and fluorescent qualities of many of these compounds are known and some are available commercially. See U.S. Patent Application Serial No. 201,465 and references cited therein, particularly, references 2-5 in that application. For certain applications, such as fluorescence polar¬ ization assays, preferred are azaporphyrin derivatives which exhibit a high degree of polarization, that is, those which emit strongly polarized light. For these applications, preferred are macrocycles having lower degrees of symmetry, preferably having lower symmetry than D 4h . One preferred group includes macrocycles having at least one fused aromatic ring. Thus, preferred macro- cycles include azaporphyrin derivatives having fused aromatic rings at positions which result in decreased symmetry. Preferred classes of azaporphyrin derivatives comprise derivatives of monoazaporphyrin, diazaporphyrin, and triazaporphyrin having lower than D 4h symmetry. B. Preferred Solubilizing Polyoxyhydrocarbyl Moieties Preferred solubilizing polyoxyhydrocarbyl moieties include water soluble carbohydrates such as glucose, sucrose, maltotriose and the like; water soluble carbo¬ hydrate derivatives such as gluconic acid and mannitol, and oligosaccharides; polypeptides such as polysine and naturally occurring proteins; and water soluble polymers such as polyvinylpyrrolidone, poly(vinyl alcohol) , poly (ethylenimine) , polyacrylic acid, polyacrylamide, ethylene oxide copolymers such as Pluronic™ (a polyether) and Tetronic™ (BASF) polyol surfactants and, in particular, polyethers such as other polyoxyalkylenes including poly (ethylene glycol) , or other water soluble mixed oxyalky- lene polymers, and the like. A particularly preferred class of solubilizing poly¬ oxyhydrocarbyl moieties comprises poly(ethylene glycol) (PEG) and poly(ethylene glycol) derivatives, such as poly(ethylene glycol) monomethyl ether. Other suitable PEG derivatives include PEG-silicon derived ethers. Many of these polymers are commercially available in a variety of molecular weights. Others may be conveniently prepared from commercially available materials, such as by coupling of an amino-PEG to a haloalkyl silyl or silane moiety. When linked to a fluorophore moiety, these polyoxyhydro¬ carbyl moieties impart particularly advantageous qualities of solubility in aqueous solution with improved measured fluorescence decay time, and improved fluorescence inten¬ sity. Moreover, the resulting marker components are water soluble and show decreased non-specific binding, especi¬ ally decreased binding tc serum albumin which has here¬ tofore been a problem with certain fluorophores, parti- cularly porphyrin or phthalocyanine dyes which have been functionalized with groups such as sulfonate to impart increased water solubility to the molecule. Non-specific binding of fluorophore or marker component impairs the accuracy of the resulting immunoassay. These marker components which comprise fluorophore linked to PEG may also exhibit improved fluorescence intensity in aqueous solution with decreased quenching. Suitable PEGs may vary in molecular weight from about 200 to about 20,000 or more. Choice of a particular mole- cular weight may depend on the particular fluorophore chosen and its molecular weight and degree of hydropho- bicity, as well as the particular application for which the fluorophore-PEG complex is to be used. C. Absorbance and Polarization Behavior of Preferred Marker Components These marker components which comprise a central atom (for example, silicon) coupled to two PEG moieties may be characterized by measurements of transient state fluores¬ cence. In such measurements the intensity of the two components polarized either parallel or perpendicular to the direction of polarization of the exciting pulse is monitored over a time period equal to about 3 times the decay time of the marker component. Such curves reflect extinction coefficient, quantum yield, decay time and state of polarization and supply sensitive indications on the chemical and physical condition of the marker component. For example, if the excited state is being deacti¬ vated or converted to the triplet state the overall intensities are lowered and the decay times shortened. If the rotary brownian motion of the molecule is being altered by an increase in viscosity or by being bound to a large molecule, the ratio of the intensity of the paral¬ lel to the perpendicular component is increased. Some marker components according to the present invention show, within experimental error of about 5%, the same intensities, decay time and polarization in DMF (an organic solvent) as in SAP (saline azide phosphate, an aqueous neutral buffer) . To some extent these properties are shared by other marker component preparations. A distinctive and important property of the marker compo¬ nents of the present invention is a insensitivity to (and lack of binding to) the components in serum which is evi¬ denced by a lack of any measured effect of serum on the intensities, decay time or relative magnitudes of the polarized components of the fluorescence. This property is crucial for the marker components to be useful for applications such as assays using biological materials. D. Preparation of Preferred Marker Components According to one method of preparing the preferred marker components of the present invention, the appropri¬ ate fluorophore moiety having hydroxy or halide groups as axial ligands is reacted with a reactive form of the solu¬ bilizing polyoxyhydrocarbyl moiety in a ligand exchange reaction according to the general reaction scheme: Mcl-CA- (X) 2 + 2 (SM) → Mcl-CA-(SM) 2 + 2X wherein Mel denotes the macrocyclic ligand, CA the central atom, X the displaced ligand and SM the solubilizing moiety. This reaction may be carried out neat or, if desired, in solvent. Suitable solvents include quinoline, THF, DMF, imidazole and the like. Suitable reaction tem¬ peratures may vary, depending on the nature of the macro- cyclic starting material and the solubilizing group. The reaction is generally complete in about 2 minutes to about 24 hours. The reaction mixture can be conveniently heated under reflux or by means such as a sand bath. For con¬ venience, the reaction may be carried out at ambient pressure. It is believed that this reaction takes place in two steps, with one polyoxyhydrocarbyl group coordinating as an axial ligand at a time. When used as fluorescent labels in fluorescence immunoassays, these marker components may be linked to one member of a specific binding pair ("labelled binding part¬ ner") or an analog of such a member. The marker component may be directly attached or conjugated thereto or attached or conjugated via a linker arm. II. Caged Dicarboxy Silicon Phthalocyanine Dye Example 1 Preparation of a Caged Dicarboxy Silicon Phthalocyanine Dye Unless otherwise stated, all chemicals used in the synthesis of phthalocyanine derivatives were purchased from Aldrich Chemical Co., Milwaukee, WI. Amino- terminated polyethylene glycol and phthalocyanine deriva¬ tives were synthesized according to published procedures. See, e.g. , Reference 18 of U.S. Patent Application Serial No . 701,449. A. Preparation of Diiminoisoindoline In a three-neck, 100 ml round-bottom flask fitted with a reflux condenser and a gas inlet tube was placed phthalonitrile (12.8 g) , and methanol (50 ml) , and the mixture was stirred while ammonia gas was slowly intro- duced. In order to prevent the possible flow of the reaction mixture into the ammonia source, and in-line trap was employed. After the reaction mixture appeared to be saturated with ammonia, 0.33 g of dry potassium tertbut- oxide was added with stirring. Stirring was continued and the reaction mixture was heated to reflux for three hours with continued introduc¬ tion of ammonia. Care was taken to avoid fouling of the gas inlet with the crystalline product. At the end of the reflux period a pale green solid had formed. The solid was collected by filtration and washed with a small volume of cold (4°C) methanol. (This compound is appreciably soluble in methanol. ) This material was dried and used for the next step without further purification. Yield was 7 g (about 50%) . B. Preparation of Dicvanodiiminisoindoline 1,2,4,5-Tetracyanobenzene (Pfaltz & Bauer, 0.5 g, 2.8 mMol) was suspended in methanol (10 ml) in a three-neck round-bottom flask fitted with a reflux condenser and a gas inlet tube. The mixture was stirred at 25°C without external cooling while ammonia gas was rapidly introduced. During the first two minutes of ammonia introduction the temperature of the reaction mixture rose to greater than 50°C and the suspended solid dissolved completely. Within 5 minutes a precipitate began to form. Stirring at 40- 50°C with slow introduction of ammonia was continued for 1 hour. The precipitated solid was collected by filtra¬ tion, washed with methanol, and dried. This product exhibited a very low solubility in methanol. C. Preparation of Dicvanosiliconphthalocyanine Dichloride (Compound I) In a dry 50 ml round-bottom flask was placed dicyano- diiminoisoindoline (350 mg, 1.8 mMol) along with diimino- isoindoline (1.0 g, 6.9 mMol) and quinoline (Fluka, 20 ml) . The mixture was stirred at 25°C while silicon tetra- chloride (Aldrich, 2.0 ml, 18 mMol) was added dropwise over a period of 1 minute. The flask was then fitted with a reflux condenser (using teflon tape) and a calcium chloride drying tube and stirred for one minute at 25°C. At this time the reaction flask was lowered into a large oil bath maintained at 180-185°C and efficient mag¬ netic stirring was continued for 30 minutes. The oil bath was then removed and the contents of the flask were allowed to cool to room temperature. The dark reaction mixture was carefully treated with water (5 ml) and then diluted with 45 ml of a 30% HCl solution. The resulting dark precipitate was collected by filtration on a 10 cm Buchner funnel. Washing with water and then acetone left a blue solid (1 gram) which was air dried and used without further purification for the next reaction step. D. Hydrolysis of Dicyanosiliconphthalocvanine Dichloride (Compound II) The crude dicyanophthalocyanine from step (C) (1 gram) was placed in a flask with a stir bar and 6 ml of concentrated sulfuric acid and stirred at 50°C overnight. The mixture was then carefully diluted with 4 ml water and heated to 100°C for an additional 20 hours. Cooling and dilution with water (20 ml) gave a blue precipitate which was collected by filtration and washed with water. The solid was then transferred to a flask along with a stir bar and 20 ml of a 1.0 M potassium carbonate solution and stirred and heated at reflux for one hour. The suspension was then slowly and carefully acidified with concentrated HCl and then filtered and the resulting solid was washed with water and acetone and dried in a desiccator. This material (0.7 g) was used without further purification in the next step. E. Preparation of 2,3-Dicarboxyphthalocvaninato-bis- T3- (lH-imidazol-1-ylcarbonyl)aminopropyl-dimethylsil- anolatol silicon (Compound III) The crude dicarboxy silicon phthalocyanine dihydrox- ide from step (D) (85 mg) was placed in a vial along with a stir bar and imidazole (160 mg, 2.3 mMol) and 1 ml of dry DMF. The mixture was stirred for 5 minutes at 25°C andthen3-isocyanatopropyldimethylchlorosilane (Petrarch, 110 μl, 0.68 mMol) was added to the stirred mixture over a period of 0.5 minutes. The vial was capped in order to exclude moisture and stirring at 25°C was continued for 20-40 hours. (A 40 hour reaction time appeared to result in an improved yield.) The vial was then opened and the dark blue mixture was diluted with methanol (4 ml) and filtered through #545 celite to remove solids. The fil¬ trate was concentrated on a rotovap using high vacuum and a water bath maintained at 40°C. The dark residue was then slurried with silica gel (1-3 g) and methanol (5 ml) and the methanol was removed on a rotovap under aspirator pressure. The blue residue was then suspended in toluene and transferred to a silica gel column prepared from 15 ml 23-400 mesh silica gel (EM Science) and toluene. This column had been washed with 50% methanol in toluene. Increasing the solvent polarity by increasing the methanol content of the solvent to 16% brought about the migration of a distinct band which was collected. This material was saved but not used for further transformations. Increasing the solvent polarity by slowly increasing the methanol content of the eluant to 30% brought about the migration of a second blue band which was collected within a 20 ml volume of 30% methanol. This material was transferred to a round bottom flask. Removal of solvent on a rotovap under high vacuum at 25°C left a residue which appeared to include an appreciable quantity of imi- dazole along with the blue dye. This material was used without further purification for the next step. The yield of compound III was approximately 3 mg. F. Preparation of Amine-Terminated Polyethylene Glycol Poly(ethylene glycol) monomethyl ether (Aldrich, average M.W. 2000, 10 g, 5 mMol) was placed in a 100 ml round-bottom flask along with a stir bar and 55 ml toluene. The flask was fitted with a short-path distil¬ lation apparatus and immersed in a heating bath. Toluene was slowly distilled at 760 mm Hg until the distillate was no longer cloudy. This required the removal of about 15 ml of toluene. The relatively water-free PEG solution was allowed to cool to 40°C. When this temperature had been attained, carbonyldiimidazole (Aldrich, 1.2 g, 7.5 mMol) was added to the stirred solution in one portion. Stirring at 30- 40°C was continued overnight with protection from atmos- pheric moisture. Water (100 μl, 3.75 mMol) was then added to the reac¬ tion mixture and efficient magnetic stirring was continued until the evolution of C0 2 gas could no longer be observed (about 15 minutes) . Most of the toluene was removed on the rotovap at 30°C under high vacuum leaving a viscous, colorless oil. This material was diluted with isopropanol (20 ml) and added to a stirred solution of 1,2 ethylenediamine (Fluka, 6.7 ml, 100 mMol) in isopropanol (15 ml) over a period of five minutes. After completion of the addition the clear solution was maintained at 40°C for four hours. At this time isopropanol (150 ml) was added to the reaction mixture. The diluted solution was allowed to stand at 4°C overnight, resulting in the formation of a voluminous mass of white crystals. This solid was col- lected on a 10 cm Buchner funnel, and subsequently recrystallized from isopropanol. Drying under high vacuum over sulfuric acid afforded 7 grams of the crude amine, suitable for use as a reagent. Structure of the product was confirmed by IR. The amine content of polyethyleneglycol amine, pre¬ pared as outlined above, was determined to be > 70 mole% by the following method: 25 ml of 10% solution of the amine in methanol was allowed to react with an equal volume of a 6% solution of maleic anhydride in THF. The reaction mixture was allowed to stand for 0.5 hours at 25°C and was then diluted to 1.0 ml with methanol. A 5 μl aliquot of this final solution was injected on to an analytical RP18 reverse phase HPLC column using 30% methanol in water as the initial mobile phase. Using n-propylamine as an internal standard allowed for accurate-quantification of the UV-absorbing acyl-PEG derivative, which was eluted in 80% methanol and was detected at 254 nm. Analysis of the infrared spectrum of amine-terminated PEG can also provide a convenient means of estimating the product yield. G. Reaction of Compound III with Amine-Terminated Poly¬ ethylene Glvcol (Compound IV) The product of step (E) (Compound III) (3 mg, 5 x 10 ~3 mMol) , which had been obtained in partially purified form by chromatography on silica gel, was dissolved in methanol (1 ml) . The mixture was stirred while amine-terminated PEG (product of step (F) , 100 mg, 5xl0 "2 mMol) was added. The resulting deep blue solution was heated to reflux for one hour. Removal of methanol under aspirator pressure at 25°C left a viscous blue oil which was taken up in water (0.5 ml) and applied to a small (10 ml wet volume) DEAE Sepha- dex anion ion exchange column (Pharmacia, 3.5 meq/g, 40- 120 micron, basic form < 1M K 2 C0 3 ) . The water-soluble blue dye was retained quantitatively by the column. The column was washed with water (15 ml) and the blue dye was then eluted in greater than 70% yield with 10-20 ml of a 15% aqueous acetic acid solution. Water and acetic acid were removed under high vacuum and the blue residue was taken up in a small volume of methanol and applied to a C18 reverse phase semi-prepara¬ tive HPLC column. The major product, detected at 675 nm as a single peak, eluted with 80% aqueous methanol (con- taining 0.6% acetic acid) and comprised about 50% of the sum of the material which was recovered from the column. Fractions containing the major product were combined and solvent was removed under high vacuum leaving a blue resi¬ due (approx. 0.5 mg, 10 '7 mMol). NMR (DCC1 3 : δ -2.85 (5, 12H) , δ -2.29 (m, 4H) , δ -1.30 (m, 4H) , 5 1.80 (m, 4H) , δ 3.6 (br.s, 300-400H) , δ 8.39 (m, 6H) , δ 9.68 (m, 6H) , δ 10.56 (S, 2H) . Note: Because the sample had been previously dissolved in D 2 0, the acidic protons, RCOOH, were not observed. Fig. 1 is a typical HPLC chromatogram of this prepar¬ ation (compound IV) . The fraction containing compound IV, with retention time of approximately 25-26 minutes, was designated "B" fraction. The yields for a typical dye preparation range from 25-65% of this fraction. Fractions from several chromatographic runs were pooled, dried in vacuo and analyzed. The absorbance of the "B" fraction was measured in a Perkin-Elmer spectrophotometer using various solvents. As shown in Fig. 2, very little "sol¬ vent sensitivity" can be seen between methanol, dimethyl- formamide and FPIA buffer (100 nM phosphate pH 7.5 with 0.01% gamma globulin). The fluorescence decay time for the "B" fraction was determined to be 4.3 nanoseconds. The measurements were made on the "Diatron Analog System" . In the Diatron Analog System, transient-state fluorescence was detected using a high speed, "gateable" photo-multiplier tube (PMT) . The combination of being able to rapidly change the PMT gain and the use of high power laser pulses enabled the viewing of the fluorescence decay of dyes with a single excitation pulse. In practice, many pulses were averaged to obtain improved data. These analog signals coming from the PMT were captured by a digitizer which took the analog signal and cut it into 512 time bins for analysis. The Diatron Analog System is diagramed in Fig. 3. The tunable dye laser used was a PTI model PL2300 nitrogen laser with a dye laser module. By changing the laser dye and adjusting the dye laser grating, 600 picosecond pulses with peak power of near 40 KWatts could be generated at wavelengths from 340 to 900 nm. A beam splitter was used to send a portion of each pulse to a pulse detector which consists of a high speed Hamamatsu photo diode. The resulting output of the photo- diode was fed into a pulse shaper which converted the resulting 800 picosecond (ps) pulse into a 100 nanosecond (ns) pulse. This 100 ns pulse was then used as a gate for the Hamamatsu microchannel plate PMT whose gain was changed by 10,000 within a 2 ns time period. The PMT stayed at the high gain until the 100 ns was over. The dye laser module, reaction cell and pulse detector was positioned and connected such that the PMT was gated to its high sensitivity state approximately 2 ns after the laser pulse passed through the reaction cell. A filter was positioned in front of the PMT to guard against high scatter signals when required. A lens was used to image the fluorescence onto the PMT microchannel plate. Also, a rotatable polarizer was positioned in the output optical path to measure the time dependent polari¬ zation of the fluorescence. High voltage from 1000 to 3400 volts was supplied to the PMT. The output of the PMT was connected to a Tek- tronix 7912AD Programmable Digitizer. A computer was used to trigger the laser. The laser output was detected by the digitizer via a connection to the pulse detector (not shown) . A programmable sweep on the digitizer set up the time spread to be measured after the laser pulse from 10 ns to as high as several seconds. Typically, the system was operated such that 512 data points were generated over a 20 ns time period. The natural log (In) (intensity) of the dye prepara¬ tions was plotted versus time and subjected to least square linear regression analysis. These data are shown in Fig. 4. The dye preparations were analyzed for their inter¬ action with serum protein. The dye preparations were adjusted to 5 x 10" 9 M/L in FPIA buffer. These dye prep- arations were added to the following solutions to a final dye concentration of 5 x 10" 11 M/L: FPIA buffer, 0.5% bovine gamma globulin, 5.0% bovine serum, 5.0% normal human serum, 5.0% pooled human serum and 5.0% whole blood lysate. These data are shown in Fig. 5. Typically, when a dye binds to a protein non-specifically (as can be seen with the "C" fraction) , a significant increase in fluor¬ escence polarization occurs. This makes it impossible to distinguish the specific polarization due to antibody binding from the non-specific due to protein-dye inter- action. The "B" fraction showed only minimal interaction over buffer as determined by measurement of transient state polarization. Example 2 Linkers In certain polarization assays, it is advantageous to use a spacer or linker. These linker or spacer arms are useful when different ligands are terminated by either a carboxyl or amino group. In addition, such compounds are important when the probe needs to be separated (stood off) from the molecule with the antibody binding epitope. This may be necessary to reduce the potential of non-radiated transfer of energy when antibody binds the specific epi¬ tope and/or to eliminate stearic hinderance. These linker/spacer arms are generally the same in both the ligand-probe and ligand-protein immunogen used to raise antibodies to the ligand, in order to create a specific binding pair. In polarization immunoassays, it is desir¬ able that the spacer create a relatively inflexible linker moiety. Because the caged dicarboxy silicon phthalocyanine is a carboxy-terminated dye, it is advantageous to have an amino terminated dye coupled to a carboxy terminated lig¬ and. Various linkers (spacer arms) have been evaluated. Such compounds include piperazine, ethylenediamine, hex- anediamine, 6-amino hexanoic acid, 5-aminobutanoic acid, 12-aminododecanoic acid, alanine and other amino acids. The following methodology for preparation of the phthalocyanine-12 amino dodecanoic acid compounds is an example of the general reaction for such linkers: To 1.0 mg of caged phthalocyanine dye (the "B" fraction of step G of example 2) in 200 μl of 50% DMF in water was added 2 mg of 1-hydroxybenzotriazole (HOBT) and 1 mg 12-amino dodecanoic acid.. The suspension was gently warmed until all ingredients were dissolved. This took from 1-2 hours. At this time 3.0 mg of 3-dimethylaminopropyl carbodiimide was added and mixed thoroughly. The reaction mixture was allowed to react overnight at 4°C. The reaction became slightly turbid and was clarified by centrifugation. The new abducts were purified on reverse phase C-18 columns by HPLC. When 12-aminododecanoic acid was used as a linker, the polarization in glycerol of the dye increased from p = 0.280 to p = 0.340. Concomitantly, a 10 nm shift to 690 nm occurred, which matches commercially available 690 nm laser diodes . The change increased the dynamic range of the assay from 0.03 to greater than 0.30 millipolarization in buffer when bound to an antibody molecule. In addi- tion, the 10 nm shift increased the signal-to-background ratio by moving away from the excitation maximum of fluor- escing background molecules found in biological fluids . The absorbance spectrum in methanol for the purified caged dicarboxy silicon phthalocyanine dye-linker is shown in Fig. 6. There is a 10 nm shift from 680 for the frac¬ tion "B" dye (Fig. 2) , to 690 nm for the dye-linker. In addition, transient state fluorescence polarization was measured on the Diatron Analog System described in Exam¬ ple I, in FPIA buffer and glycerol at 680 nm and in glycerol at 690 nm. These data are shown in Figs. 7 and 8. III. Synthesis of Caged Dicarboxy Silicon Phthalocyanine Diσoxin Probe Digoxin is a glycosylated steroid which, when used in patients with congestive heart failure, increases cardiac output, decreases heart size, venous pressure and blood volume, and relieves edema. As noted above, digoxin has a very narrow therapeutic range (serum levels of 0.5 to 2.5 ng/ml) and is generally toxic at concentrations greater than 2.1 ng/ml. Accordingly, there is a need for a digoxin assay which can accurately and precisely deter¬ mine digoxin concentrations at these levels. Example 3 Digoxin Probe Preparation: Caged Dicarboxy Silicon Phthalocyanine-Digoxigenin A. Preparation of 3-Ketodigoxigenin A mixture of 488 mg digoxigenin, 7.5 ml toluene, 3.75 ml cyclohexanone, and 550 mg aluminum isopropoxide was heated under reflux for 2.3 hours and then concentrated in vacuo to half of its original volume. Two hundred μl water was added and the mixture was evaporated in vacuo to dryness. The powdery solid was dried j-n vacuo over over¬ night. The dry residue was stirred in 25 ml methanol and the resulting mixture was filtered. The residue on the funnel was washed with 25 ml methanol. The filtrate and washing were combined and evaporated in vacuo affording 920 mg white solid. B. Preparation of 3-Aminodigoxigenin A mixture of 920 mg 3-ketodigoxigenin, 693 mg ammo¬ nium acetate, and 780 mg, NaBH 2 CN was stirred in 48 ml methanol at room temperature overnight. Concentrated HCl (35 ml) in 20 ml methanol and 5 ml water were added. After gas evolution had subsided, the solvent was removed in vacuo. The residue was stirred in 15 ml water and then extracted with 2 x 20 ml methylene chloride. The water phase was gummy material was evaporated in vacuo and the residue was dried leaving a granular solid. This dry- solid was extracted with 2 x 20 ml dimethylformamide (DMF) and the solution centrifuged. The clear DMF solution was evaporated in vacuo affording 684 mg white solid. The entire amount was dissolved in 25 ml methanol and the solution was stored at -20°C overnight. A white crystal¬ line material, which had deposited, was removed by fil- tration and washed with 300 μl cold methanol. The fil¬ trate was applied to two washed EM 5766 silica TLC plates. After being developed in 90 ml chloroform + 25 ml methanol the chromatogram showed 7 bands visible under 254 nm uv. Band Number 1, Rf = 0.10, was removed from the plates, extracted with 4 x 40 ml methanol and the Si0 2 was cen¬ trifuged out. The supernates were combined and evaporated in vacuo affording 70 mg white solid. C. Synthesis of Probe The digoxin probe was prepared as follows: .2 mg of 3-aminodigoxigenin was placed in a 3.0 ml reaction vial and dissolved with 100 μl DMF. In a separate vial, 1.0 mg of caged dicarboxy silicon phthalocyanine (Compound IV from Example 1(G)) was dissolved in 400 ml DMF and then transferred to the reaction vial along with 200 μl of wash DMF for a total of 600 μl,. 4.2 mg of 1-hydroxybenzotria- zole (HOBT) was added to the reaction vial, which was then dissolved and mixed well. To make the final reaction mix¬ ture, 10.5 mg of l-ethyl-3- (3-dimethylaminopropyl/carbodi- imide) -HCl (EDAC) was added and mixed thoroughly. The reaction mixture containing digoxin-phthalocyanine probe was stored at 4.0-8.0°C overnight. D. Purification of Probe The digoxin-phthalocyanine probe was purified as fol¬ lows: a slurry of 5 gm C-18 was made in acetone and poured into a 1x15 cm glass column. The acetone was removed by the application of light pressure, and the column was equilibrated by the addition of 4 column vol¬ umes of 70% methanol/30% water. The reaction mixture containing digoxin-phthalocyanine probe was applied to the column and flushed with 70% methanol/30% water. The probe was eluted with 80% methanol/20% water, concentrated by vacuum and further purified by two subsequent passes on HPLC. After the second chromatograph on HPLC, the probe was brought to dryness in vacuo. A portion was dissolved in methanol and a portion was dissolved in 100 mM NaP0 4 buffer containing 0.1% sodium azide and 1.0% bovine gamma globulin (pH 7.5) . Fig. 9 depicts a chromatograph of the HPLC method semi-prep C-18 column with a mobile phase and gradient elution of methanol/water. Fig. 10 depicts the structure of the digoxin-phthalocyanine probe. E. Analysis of Probe The probe was analyzed in a Perkin-Elmer spectro- photometer (Lambda 4 c) in two solvents, methanol and 100 mM phosphate, pH 7.5. Figs. 11 and 12 are repre- sentative spectra. Fluorescence decay time was determined to be 4.7 ns using the Diatron Analog System described in Example 1 (Fig. 13) . F. Linearity in Buffer and 1.0% Bovine Serum Albumin To determine the sensitivity and linearity of the transient state measurement system and development of a digoxin assay, it was necessary to determine the concen¬ tration of the phthalocyanine-digoxin probe. The probe was purified by one additional pass through HPLC for a total of three (3) passes through HPLC chromatography using reverse phase C18 columns. The probe was dried under vacuum and dissolved in a 100 mM phosphate buffer, pH 7.5 containing 0.01% bovine gamma globulin. The absorbance maximum was determined and the absorbance of the probe solution was measured. Concentration was determined using the following formula: A = αBC, where A = Absorbance, a = extinction coefficient, B = path length, and C = concentration. Thus, C = A In this example: αB a = 1.6 X 10 s , B = 1 cm, and A = 0.227. Accordingly, the concentration of the stock phthalocyanine-probe solution was = 1.45 X 10 "6 M/L. Based upon this value of 1.45 X 10 "β M/L, dilutions of appropriate concentrations were prepared in FPIA buffer and in 1.0% bovine serum albumin. The results are shown in Fig. 14. The linearity of intensity of probe from 6.5 X 10 "9 M to 1 X 10- 13 M digoxin in ' both FPIA buffer and FPIA buffer with 1% BSA demonstrates the ability of the probe to func¬ tion in a protein solution without interaction with bind- ing components. As can be seen from the data presented in Table 1, the polarizations of free dye ("B" fraction) and free probe in various sera are similar, with the polarizations being slightly higher for the digoxin probe. This is consistent with the increase in molecular size and asym¬ metry of the probe. In addition, the changes observed in buffer vs the serum solutions is consistent with a change in viscosity as defined by the following equation: r = 3nV RT where: R = gas constant, T = temperature (in °K) , n solution viscosity, and V = volume of molecules. Table 1 Phthalocyanine Digoxin Probe: Serum Interactions Comparison of milli-Polarization (mP) "B" Fraction Digoxin Probe G. Serum Urine Interactions A comparison of a fluorescein-digoxin probe analyzed on the Abbott TDx ® Fluorescence Polarization Analyzer and the phthalocyanine digoxin probe analyzed with the Diatron FAST-60 Analyzer is presented in Fig. 15. In this exam- pie, both probes were tested at the normal (working) concentration used when performing a digoxin assay with the TDx™ and FAST-60 analyzers (i.e.. 2.5 X 10 "10 and 5.5 X 15 "11 M/L) . See Example 4 for a description of the Diatron FAST-60 Analyzer. In this figure, the intensity levels are plotted as background equivalents. As can be seen from Fig. 15, the fluorescein probe is only slightly detectable above background in 5% serum and completely non-detectable in 10% urine. In contrast, the phthalocyanine digoxin probe is detectable at a very sig- nificant level above background in both the same serum and urine samples. IV. Digoxin Assays Example 4 Competitive Serum Assay for Digoxin: Sequential Binding Procedure Digoxin reacts with serum albumin and other serum proteins at many reaction sites. Probes made with a fluorescent dye and digoxin will also react. "Nonspeci¬ fic" binding or serum protein interactions were minimized in this procedure by the action of the cyclodextrin, which has an affinity for digoxin which exceeds digoxin's affi¬ nity for constituents in serum. Thus the cyclodextrin interferes with the binding of digoxin with serum consti¬ tuents, but allows for binding of digoxin with digoxin antibody. Thus, the assay was designed to allow both the serum digoxin and the digoxin probe to react with the digoxin antibody. 100 μL of serum sample was mixed with 25 μL of rabbit antidigoxin and 500 μL Bufferl (100 millimolar phosphate buffer, pH = 7.6 with 0.01% bovine gamma-globulin, 0.5% gamma-cyclodextrin and 0.1% sodium azide). The mixture was incubated for 5 minutes. 25 μL of digoxin probe (as prepared according to Example 3) and 200 μL of Buffer2 (100 millimolar phosphate buffer, pH = 7.6 with 0.01% bovine gamma-globulin and 0.1% sodium azide) were added and the mixture was incubated for 20 minutes. In a study of 20 random human serum samples it was found that the serum-digoxin probe interaction would vary from sample to sample, and that the variation may be as much as 10-15 millipolarization units. The buffers in the present example were formulated to eliminate this varia¬ tion to a relatively constant millipolarization of 70. Transient state polarization was measured as described in Studholme, et al. , Patent Application entitled "Fluorometer Detection System, " Lyon & Lyon Docket No. 195/129. The transient state optical system was installed in the Diatron "FAST-60 Analyzer, " which contains a laser diode operating at 685 nm was pulsed at a 10 MHz rate. Typically, the laser "on" time was approx¬ imately 3 nanoseconds. Photons from the solution were detected using a photomultiplier tube (PMT) operating in a single photon counting mode. The photon event along with the relative time of the photon event as compared with the laser pulse time was determined. By storing the individual photon event times a histogram of frequency of photons as a function of time was generated. The Diatron FAST-60 Analyzer includes a transient- state optical system installed in an automated fluores¬ cence reader designed to measure fluorescence from immuno¬ assay reactions. The reader contains the optical system, motor control for position reaction cuvettes in front of the optical system, thermal control to hold the system at 35°C and a computer link to control the reader, analyze and display results and print those results. For immuno¬ assay use, the results were formatted into transient-state polarization units or, by using a calibration curve, the results were transformed into concentration units of the analyte being measured. Commercial serum calibrators for digoxin determina¬ tion (obtained from Abbott Laboratories) were analyzed to obtain a standard curve. Sample blanks were prepared for each sample or calibrator by performing the same steps with the exception that buffer was added in place of the digoxin probe. The sample blank was measured and sub¬ tracted from the measurements for all reaction mixtures. The procedures were performed at 35°C. Fig. 16 shows a comparison of digoxin calibration curves by a standard fluorescence polarization procedure (Abbott's TDx ® Fluorescence Polarization Analyzer) and the homogeneous sequential binding assay procedure described in this Example. Fig. 17 displays a correlation plot of 37 serum samples assayed by a commercial digoxin test system manufactured by Abbott Laboratories (TDx ® Digoxin II In Vitro Test, Product #9511-60) and assayed by the digoxin assay procedure described in this example. A correlation of 0.96 and a slope of 0.98 were determined. The slope and y-intercept indicate no systematic bias. Example 5 Competitive Serum Assay for Digoxin: Dilution Jump Procedure The dilution jump procedure described in this Example allows the assay to be performed in the presence of high concentrations of serum, and was designed to reduce "non¬ specific" interactions which compete with the antibody for binding to the digoxin and digoxin probe. While not wish¬ ing to be bound by any particular theory, applicants believe that when sample, antibody and digoxin probe are incubated in a small reaction volume, the "nonspecific" interactions initially compete with the antibody for binding to digoxin and digoxin probe. When the solution is diluted, the "nonspecific" protein interactions tend to disappear rapidly and only the specific antibody reaction remains. To perform the dilution jump procedure, 200 μL of serum calibrator (Abbott Laboratories) or serum sample was mixed with 250 μL of antibody (rabbit anti-digoxin anti¬ body) , 250 μL of digoxin probe and 1000 μL FPIA buffer. The mixture was incubated for 30 minutes at 35°C. A variable volume of the reaction mixture was removed and added to 900 μL of FPIA buffer. For example 170 μL of reacted mixture in 900 μL of buffer provided a final probe concentration of 5 x 10 "11 M. As the reaction mixture was diluted, the degree of nonspecific binding decreased while the amount of specifi- cally bound probe remained nearly constant. As shown by the results depicted graphically in Fig. 18, for non- diluted reaction mixture (probe concentration of 3.5 x 10" 10 M) , the resulting polarization was 189 mP. As the reaction mixture was diluted, the polarization decreased until it reached a limit (near 152 mP) at a 7-fold dilu¬ tion of the reaction mixture. An alternate dilution jump procedure was also done in which 20 μl of commercial serum calibrator or serum sample was mixed with 80 μl of lysing/buffer (5 x 10 "5 M/L stearyl-lysolecithin in .001 M/L Tris HCl buffer at pH 8) diluent, and 10 μl of rabbit anti-digoxin was added and mixed. This mixture was allowed to incubate at 35°C for 5 minutes. At this time, 25 μl of digoxin probe was added and incubated an additional 15 minutes. To this reaction mixture 1.0 ml of FPIA buffer was added (dilution jump) , vortexed and the transient state polarization measurements were made in the Diatron FAST-60 Analyzer described in Example 4. The calibration curve using the dilution jump pro¬ cedure is shown in Fig. 19. Example 6 Competitive Serum Assay for Digoxin: Signal-to-Background Comparisons for Transient-State and Steady-State Measurements The signal-to-background ratios for steady state and transient state measurement were determined as follows : 1. The steady state fluorescence intensity measure¬ ments were made on the Abbott TDx ® Fluorescence Polariza¬ tion Analyzer using the "Photo Check Mode." Both back¬ ground and fluor measurements were taken by removing the reference solutions from the calibration carousel and substituting varying dilution of fluorescein from 1.7 X 10 "8 M/L to i.7 X 10 "12 M/L in 1.0% bovine serum albumin. 2. The steady state fluorescence of the caged sili¬ con phthalocyanine-digoxin probe was measured in a modi- fied TDx ® Fluorescence Polarization Analyzer. These modifications were made by replacement of the input filter with a 680, 10 mm 1/2 bandwidth filter and the output with a RG715 color glass filter. The concentrations of the probe solutions were determined in a similar manner as those determined in Example 3. Dilutions were prepared in 1.0% bovine serum albumin in concentrations of 1.4 X 10 "8 M/L to 1.4 X 10 ~12 M/L. The measurements were made as in 1 above. 3. The transient state measurements were made in the Diatron FAST-60 System using the same solutions as in 2 above, but at concentration of 1.4 X 10 -9 M/L to 1.4 10 '14 M/L. The data are summarized in Table 2. The signal-to- background data is represented as a ratio (signal counts/ background count) . Table 2 Signal-to-Background Ratio Comparisons Serum Calibrator 680 nm Probe Intensity Blank Intensity Probe/ Fluorophore (counts/15 sec) (counts/15 sec) Blank Steady-State " 437,22 466,848 6.5 Transient-State 264,404 4,048 65.3 Thus, applicants have shown that steady state assays can be configured with acceptable signal-to-background ratios using the caged dicarboxy silicon phthalocyanine digoxin probe which is measured at 680 nm. There was an approxi¬ mately 10-fold enhancement in this ratio when transient state techniques were used to time-discriminate against fast fluorescers within the background and scattering bands. In immunoassays which measure analytes at very low concentrations, for example, digoxin at 5 x 10" 10 to 60 x 10 "1Q M/L, the concentration of fluorescent probe in the fluorescein steady assay system is 2.5 x 10 "10 M/L. These assays require an extraction step to remove the digoxin bound to serum proteins (approximately 25-40%) and fluor¬ escers bound to proteins that interfere in the measurement of fluorescence polarization. In serum, the background fluorescence is highly polarized due to this protein bind¬ ing, which can mimic specific polarization due to antibody binding. These must be removed before the assay can be performed. Many of these fluorescers are excited by 493 nm light, which corresponds to the excitation maximum of these fluorescein based assay systems. In this example, the signal to background is at best 2.5:1. However, when unextracted serum is added as in a homogeneous assay using the fluorescein steady state measurement technique, the probe fluorescence is not detectable at the concentration of serum needed to run the assay (Fig. 15) . This principle can be illustrated by the data in Table 3. For a steady state fluorescein-based assay, the fluorophore concentration at which fluorophore signal equals background is 1.6 x 10" 9 M/L. This is far above the concentration of fluorophore needed to perform an accept¬ able digoxin assay, i.e. , an assay which can detect and quantitate digoxin at therapeutic levels. In other words, the fluor cannot be measured over fluorescence of background. As can be seen from the data in Tables 2 and 3, there is approximately an 8-fold improvement in steady state caged dicarboxy silicon phthalocyanine measurement over steady state fluorescein measurement. This improvement increases an additional 10-fold when transient state measurements are made using the caged dicarboxy silicon phthalocyanine probe. Additionally, there is a clear 100- fold improvement of the transient state measurements over the currently used fluorescein steady state measurements. Table 3 Signal-to-Background Comparison: Fluorophore Concentration Where Fluorophore Signal Equals Background Technology Fluorophore Concentration Steady State Fluorescein 1.6 X 10 "9 M/L Steady State Phthalocyanine Probe 2.4 X 10" 10 M/L Transient State Phthalocyanine Probe 1.4 X 10 *11 M/L Example 7 Competitive Serum Assay for Digoxin: High Sensitivity Assay In this assay, the sensitivity of the digoxin assay described in Example 5 is increased by a factor of 10. The concentration of caged dicarboxy silicon phthalocya¬ nine digoxin probe was determined by the procedure out¬ lined in Example 3 to be 4.2 X 10 "12 M/L. In this assay the total reaction volume was reduced by 50 percent and all reactants were reduced 10-fold. To increase the polariza¬ tion values, the incubation times were increased to 5 and 15 minutes for the sequential addition, competitive bind¬ ing format. The procedure is as follows: 50 μl of lysing/buffer (see Example 5 above) diluent was mixed with 2.0 μl serum calibrator or serum, plasma or whole blood sample and 5.0 μl of rabbit anti-digoxin antibody. This mixture was incubated for 5 minutes and 2.5 μl of digoxin probe was added and incubated an additional 15 minutes. After this incubation, 1.0 ml FPIA buffer was added as a dilution jump. The transient state polarization measurements were made on the Diatron FAST-60 Analyzer described in Exam¬ ple 4. Sample blanks were prepared for each sample or calibrator by performing the same steps, with the excep¬ tion that buffer was added in place of the probe. The sample blank was then measured and subtracted from the measurements for the entire reaction mixtures. Fig. 20 displays a calibration curve for commercial serum calibrators containing known concentration of digoxin, which were assayed using the high sensitivity procedure. Example 8 Preparation of Whole Blood Calibrators Whole blood was obtained from two donors by drawing blood into Vacutainer™ (Bector Dickinson) tubes containing EDTA anticoagulant. The tubes were mixed thoroughly on a standard laboratory sample rotator. Based on the average specific gravity of blood being 1.056, a series of six 2 ml volumes of whole blood were weighed using standard gravimetric technique. These samples were then spiked using a USP grade digoxin (200 ng/ml) to final concen¬ trations of 0, 0.5, 1.0, 2.0, 3.0, and 5.0 ng/ml whole blood. The whole blood calibrators were stored at 4.0 - 8.0 °C and were used within two weeks. Example 9 Whole Blood Digoxin Assay: Signal-to-Background Ratio, Serum Versus Whole Blood Applicants determined the signal-to-background ratio of the whole blood preparations which were prepared as described in Example 8 and compared the whole blood (i.e. , blank) intensity to the probe intensity. The resulting values comparing the whole blood and serum signal-to- background ratios are shown in Table 4. These measure¬ ments were made at working digoxin probe concentration of 5 X 10 "11 M/L in the transient state system. It can be seen that the net probe intensities remained constant even when the background intensities fluctuated. In a typical steady state fluorescein digoxin assay where the digoxin is extracted by precipitation of proteins, the average signal-to-noise ratio is 2 to 1 at probe concentrations of 2.5 X 10 "10 M/L, as contrasted with those found by homoge¬ neous transient state fluorescence for serum and whole blood of 77.6:1 and 26.7:1, respectively. Table 4 Signal-to-Background Ratio Comparisons for Serum and Whole Blood Probe Intensity Blank Intensity (counts/15 sec) (counts/15 sec) Probe/Blank Serum 113,284 1,466 77.6 Whole Blood 100,258 3,757 26.7 Example 10 Homogeneous Whole Blood Digoxin Assay — Clinical Study Previous whole blood immunoassays have been limited by many factors. For example, separation steps are required in many assay systems, enzymes and other sub¬ stances released from red blood cells cause interference in the assays, and the instrumentation is incapable of measuring analytes or reaction products through whole blood hemolysates. Applicants have developed a homoge- neous whole blood assay system which offers the clinical laboratory and other testing facilities significant advan¬ tages over currently used methods, including decreased labor cost, and decreased sample manipulation. In addi¬ tion, with a homogeneous 5 to 10 minute assay, the pro- cedure can be brought much closer to the patient, for example, to the bedside, emergency care facilities clinics and satellite testing facilities. Digoxin is widely distributed in body tissues. Serum and plasma have been the accepted samples for the assay of digoxin using the current commercially available test kits. Studies have shown a relative constant relationship between heart muscle and serum digoxin levels, thus vali¬ dating the use of digoxin serum levels in monitoring patients receiving the drug (Doherty, J.E., et. al.. 1978, "Clinical Pharmacokinetics of Digitalis Glycosides." Pro¬ gress in Cardiovascular Diseases, Vol. XXI, No. 2 (Sept./ Oct.) ) . Because whole blood has not been routinely used as a medium for assay in digoxin therapy, the following study was undertaken to determine: (1) the distribution of digoxin in serum, plasma and red cell components of blood; (2) the percentage discrepancy, if any, in digoxin levels of serum, plasma and whole blood assays; and (3) correlation among two currently commercially available assays — the Abbott TDx ® serum assay and the Dade Stratus ® serum assay — and the assay of the present invention. The clinical study was conducted using 43 patient samples, collecting 1 EDTA tube for whole blood or plasma levels and 1 tube for serum levels. Each sample pair was ana¬ lyzed for serum digoxin levels determined by the Abbott TDx ® , Dade Stratus ® and Diatron FAST-60 Systems. Plasma levels were analyzed by Abbott TDx ® and Diatron FAST-60 Systems. Whole blood levels were analyzed by Abbott TDx ® and Diatron FAST-60 Systems. The Abbott TDx ® System used the TDx ® Digoxin II In Vitro Test, Product #9511-60 (Abbott Laboratories) . The Dade Stratus System used the Dade Stratus ® Digoxin Fluorometric Enzyme Immunoassay (Dade Diagnostics Division of Baxter Healthcare Division, Miami, Florida) . The Diatron FAST-60 System used the methods described in Example 5 and the apparatus described in Example 4 and Studholme, e al. , Lyon & Lyon Docket No. 195/129. In this study, the primary concern was whether the whole blood digoxin values were similar to the serum values. Thus, to reduce the number of variables, the whole blood lysates were clarified by centrifugation before assay. The study subjects were randomly selected patients currently on active digoxin therapy. The following sam¬ ples were taken from each patient: (1) Red stopper Vacu- tainer™ tube (no EDTA) for serum collection (a minimum of 2 ml required) ; and (2) Purple stopper Vacutainer™ tube (EDTA) for whole blood assay and for plasma preparation (a minimum of 4 ml required) . Both tubes drawn at the same time. All blood, serum and plasma was stored at 4°C until assayed. All assays run within 24 hours after drawing. The Diatron FAST-60 Digoxin Assay System consisted of (1) caged dicarboxy silicon phthalocyanine digoxin probe in FPIA buffer with 1% bovine gamma globulin; (2) rabbit anti-digoxin in FPIA buffer with 0.1% bovine gamma globu¬ lin; (3) lysing/buffer diluent; and (4) FPIA buffer (100 mM phosphate buffer with 1% sodium azide and .01% bovine gamma globulin) . Assay procedures were performed as follows: 1. Serum A. Abbott TDx ® Digoxin II In Vitro Test — Performed according to manufacturer's instructions. B. Dade Stratus ® — Performed according to manufacturer' s instructions. Serum values performed by Pathology Medical Laborator¬ ies, 11180 Roselle Street, San Diego, California 92121. C. Diatron FAST-60 — See Fig. 21. 2. Plasma A. Abbott TDx ® Digoxin II In Vitro Test - Performed according to manufacturer' s instructions. B. Diatron FAST- 0 — See Fig. 21. 3. Whole Blood A. Abbott TDx ® Digoxin II In Vitro Test — Performed according to manufacturer's instructions, except for the precipitation step. Digoxin extraction from whole blood was accomplished as follows: to 360 μl whole blood, an equal volume of Abbott -Precipitation Reagent (Digoxin II) was added with immediate vortexing for 30 sec¬ onds. The conical tubes were centrifuged at 10,000 RPMs for two minutes. The slightly brownish supernate was removed very carefully with a Pasteur pipette and transferred to the sample cup, to avoid the transfer of small particles. B. Diatron FAST-60 — See Fig. 21. Red blood cells were lysed prior to assay by addition of lysing buffer (0.001 M/L Tris buffer, pH 8.0 containing 5 x 10 ~5 M/L stearyl-lysolecithin) . Palmitoyl-lysolecithin and myristoyl-lysolecithin in Tris buffer are equally effective. These reagents are preferred in that they do not interfere with the immunoassay at this concentration, and that red cell ghost particle size is reduced in 30 to 60 seconds, thus reducing any effect of light scatter dur- ing the fluorescence measurements resulting in a homoge¬ neous, non-separation whole blood assay. The results of the testing are tabulated in Table 5. The values from the TDx ® and Stratus ® are the result of single point testing. Because the FAST-60 procedure used "manual pipetting" and automated instrumental analysis, the samples were run in duplicate and the raw values averaged. The correlation data are found in Figs. 22 through 26. These include TDx ® serum versus FAST-60 whole blood (Fig. 22) , Stratus ® serum versus FAST-60 whole blood (Fig. 23) FAST-60 serum versus FAST-60 whole blood (Fig. 24) , TDx ® serum versus FAST-60 serum (Fig. 25) and Stratus ® serum versus FAST-60 serum (Fig. 26) . As can be seen in Figs. 22 and 24, a high degree of correlation exists between TDx ® serum versus FAST-60 whole blood, with R = 0.96 and 0.97, respectively. When the correlation data in Fig. 24 is compared to Fig. 23, it can be seen that the data is system consistent within the FAST-60 System. Figs. 25 and 26 show a comparison of TDx ® serum versus FAST-60 serum and Stratus ® serum versus FAST- 60 serum assay data with correlations of R = 0.96 and 0.97, respectively. -Again, it could be interpreted that a slight system bias exists. The raw digoxin values for the assays are found in Table 5. A comparison of the FAST-60 serum and FAST-60 whole blood systems with the TDx ® and Stratus ® Systems reveals only small differences between the mean values. This is surprising and remarkable when considering the differences inherent in the various methods used. A composite CV of 12.7% was found when comparing data for all assays. In addition, the digoxin values for whole blood, plasma and serum obtained on the FAST-60 system were extrapolated from a single composite calibration curve. Thus, it would appear that satisfactory digoxin values could be obtained using either specimen and extrapolation from only one calibration curve. In a clinical setting this is important in that less sample needs to be drawn from the patient, and also, any one of the blood specimen can be used in the measurement of digoxin. This saves the patient from a needless extra venipuncture and saves the laboratory time and additional cost for time and materials. The above examples involve the preparation and use of a caged dicarboxy silicon phthalocyanine digoxin probe. Those skilled in the art will appreciate that other types of fluorescent digoxin probes which comprise a detectably labeled marker component which comprises a fluorophore moiety comprising a luminescent substantially planar molecular structure coupled to two solubilizing polyoxy¬ hydrocarbyl moieties, one located on either side of the planar molecular structure, can be prepared. Those skilled in the art will also readily appreciate the fact that caged dicarboxy silicon phthalocyanine probes can be prepared for other analytes, as well. For example, small analytes such as amikacin, gentamicin, netilmicin, tobra- mycin, carbamazepine, ethosuximide, valproic acid, diso- pyramide, lidocaine, procainamide, quinidine, methotrex- ate, amitriptyline, mortripyline, imipramine, desipramine, vancomycin and cyclosporine are particularly suited for the assays described herein due to their size. For example, as described in Examples 11-17 below, such probes were prepared for digitoxin, theophylline, phenobarbital, thyroxine, N-acetylprocainamide, primidone and phenytoin. Those skilled in the art will also recog¬ nize that caged dicarboxy silicon phthalocyanine probes can be prepared for peptides. For example, as described in Examples 18 and 19 below, such probes were prepared for rubella virus peptide. Example 11 Synthesis of Caσed Dicarboxy Silicon Phthalocyanine-Digitoxin A. Preparation of 3-Aminodigitoxigenin 3-aminodigitoxigenin was prepared by procedures similar to those described in Example 3 above for the digoxin probe. B. Preparation of Probe The digitoxin probe was prepared as follows: 0.8 mg of 3-aminodigitoxigenin was placed in a 3.0 ml reaction vial and dissolved in 100 μl DMF. Caged dicarboxy silicon phthalocyanine (1.0 mg) was added to the reaction vial. Also added to the reaction vial were 0.5 mg HOBT and 2.0 mg EDAC and the resulting mixture was thoroughly mixed. The reaction mixture was stored overnight at about 4 to 8°C. C. Purification of Probe The digitoxin probe was purified by procedures similar to those described in Example 3 for the digoxin probe. The structure of the caged dicarboxy silicon phthalocyanine-digitoxin probe is shown in Fig. 27. Example 12 Synthesis of Caged Dicarboxy Silicon Phthalocvanine-Theophylline A. Preparation of Theophylline 8-Butyric Acid A mixture of 31.3 g glutaric anhydride, 25 g 5.6- diamino-1,3-dimethyl uracil, and 300 ml N, N-dimethyl- aniline was heated under reflux for 4 hours. Upon cooling, the product crystallized from the dark, clear reaction mixture. The crystals were collected by fil¬ tration, washed with benzene, then with methanol, and dried affording 187 g light yellow solid. B. Preparation of Theophylline-8- (N-2-Aminoethyl) Butyramide To a stirred mixture of 453 mg theophylline-8-butryic acid, 6 ml DMF and 4 ml (THF) was added 240 μl triethyl- amine. The resultant solution was cooled in ice and 220 μl isobutylchloroformate was added. After 1 hour the slurry was added to 2 ml ethylenediamine cooled in ice. The reaction mixture was maintained at 0°C for 6 hours and then concentrated to dryness. The residue, upon frac¬ tional crystallization from chloroform + ethanol provided 369 mg pure theophylline-8- (N-2-aminoethyl)butyramide. C. Preparation of Probe The theophylline probe was prepared as follows: 1.2 mg theophylline-8- (N-2-aminoethyl)butyramide was placed in a 3.0 ml reaction vial and dissolved in 100 μl DMF. In a separate vial, caged dicarboxy silicon phthalo¬ cyanine (1.0 mg) was dissolved in 400 μl DMF and then transferred to the reaction vial along with 200 μl of wash DMF (for a total of 600 μl DMF) . To the reaction vial was added 6.1 mg of HOBT, dissolved and mixed well. To make the final reaction mixture, 7.0 mg EDAC was added and the resulting mixture mixed thoroughly. The reaction mixture was stored overnight at about 4 to 8°C. D. Purification of Probe The theophylline probe was purified using procedures similar to those described in Example 3 for the digoxin probe. The structure of the caged dicarboxy silicon phthalocyanine-digoxigenin probe is shown in Fig. 28. Example 13 Synthesis of Caged Dicarboxy Silicon Phthalocyanine-Phenobarbital A. Preparation of Nitrophenobarbital Phenobarbital, 663 mg, was dissolved in 2.7 ml con- centrated sulfuric acid cooled in ice. With stirring, a cold solution of 0.16 ml concentrated nitric acid in 0.65 ml concentrated sulfuric acid was added dropwise over a period of 4 minutes. After 1/2 hour in the cold, the reaction mixture was poured into ice water. The precipi- tate was collected, washed with water, and dried in vacuo affording 0.03 g white solid. B. Preparation of Aminophenobarbital Nitrophenobarbital (225 mg) was stirred in a mixture of 3 ml concentrated HCl, 2 ml acetic acid and 2.5 ml THF. To the slurry mixture was added a solution of 370 mg SnCl 2 in 1 ml concentrated HCl and 1 ml acetic acid. After stirring at room temperature for 2 hours, the reaction mixture was concentrated to give an oily residue. To this residue, NaHC0 3 solution was added until the pH was about 7. The precipitate was collected, washed with water and dried in vacuo leaving 449 mg white solid. This solid was stirred in 10 ml THF and centrifuged to remove the inor¬ ganic material. The supernatant liquid was evaporated and the residue was dried in vacuo affording 138 mg light yel- low solid. C. Preparation of Probe The phenobarbital probe was prepared as follows: 1.2 mg of 5-ethyl-5- (aminophenyl)barbituric acid (P-amino- phenobarbital) was placed in a 3.0 ml reaction vial and dissolved with 200 μl DMF. In a separate vial the caged dicarboxy silicon phthalocyanine (1.0 mg) was dissolved in 200 μl DMF and then transferred to the reaction vial. To the reaction vial was added 2.4 mg HOBT, dissolved and mixed well. To make the final reaction mixture, 2.8 mg of EDAC was added and mixed thoroughly. The reaction mixture was stored overnight at about 4 to 8°C. D. Purification of Probe The phenobarbital probe was purified using procedures similar to those described in Example 3 for the digoxin probe. The structure of the caged dicarboxy silicon phthalocyanine probe is shown in Fig. 29. Example 14 Synthesis of Caged Dicarboxy Silicon Phthalocvanine-Thyroxine A. Preparation of Thyroacetic Acid Ethylenediamine To a stirred mixture of 100 mg thyroacetic acid in 15 ml pyridine was added 16 mg of N-hydroxysuccinimide and 27.6 mg N,N' -dicyclohexylcarbodiimide. The mixture was stirred for 2 hours at room temperature and transferred to 4°C for 18 hours. The crystals were removed by filtration and 8.03 mg of ethylenediamine was added to the filtrate with stirring. This reaction was allowed to proceed an additional 24 hours at 4°C and was dried in vacuo result- ing in whitish-gray powder. The material was stored at -20°C in a desiccator. B. Preparation of Probe The thyroxine probe was prepared as follows: 1.0 mg of tetraiodothyroacetic acid-ethylenediamine (Tetrac-EDA) was placed in a 3.0 ml reaction vial and dissolved in 100 μl DMF. In a separate vial, caged dicarboxy silicon phthalocyanine (1.0 mg) was dissolved in 400 μl DMF and then transferred to the reaction vial along with 200 μl of wash DMF for a total of 600 μl. To the reaction vial was added 1.8 mg HOBT, dissolved and mixed well. To the final reaction mixture, 1.5 mg EDAC was added and the resulting mixture mixed thoroughly. The reaction mixture was stored overnight at about 4 to 8°C. C. Purification of Probe The thyroxine probe was purified using procedures similar to those described in Example 3 for the digoxin probe. The structure of the caged dicarboxy silicon phthalocyanine-thyroxine probe is shown Fig. 30. Example 15 Synthesis of Caged Dicarboxy Silicon Phthalocyanine-N-Acetylprocainamide A. Preparation of Desethyl-N-Acetylprocainamide Desethyl-N-acetylprocainamide was prepared by dis¬ solving 1.0 g of p-acetamidobenzoic acid and 0.7 g N-hydroxysuccinimide in 20 ml pyridine. To this solution was added 1.4 g of N, N'-dicyclohexylcarbodiimide. The reaction mixture was placed at 4°C for 18 hours, at which time the crystals were removed by filtration. The filtra¬ tion was brought to room temperature and with stirring, 0.51 g N-ethylethylenediamine was added. Stirring con¬ tinued for 3 hours, the solution was cooled to 4°C and allowed to react for an addition 24 hours at 4°C. The second crop of crystals was removed by filtration, dis¬ solved in 25 ml of distilled water. The pH was adjusted to 10 with sodium hydroxide to form a white precipitate of desethyl-N-acetylprocainamide . The resultant precipitate was dried in vacuo and stored at -20°C in a desiccator. B. Preparation of Probe The N-Acetylprocainamide probe was prepared as fol¬ lows: 1.0 mg desethyl-Ν-Acetylprocainamide was placed in a 3.0 ml reaction vial and dissolved with 100 μl DMF. In a separate vial, caged dicarboxy silicon phthalocyanine (1.0 mg) was dissolved in 400 μl DMF and then transferred to the reaction vial along with 200 μl of wash DMF for a total of 600 μl. To the reaction vial was added 4.2 mg HOBT, dissolved and mixed well. To make the final reac¬ tion mixture, 10.5 mg EDAC was added and mixed thoroughly. The reaction mixture was stirred overnight at about 4 to 8°C. C. Purification of Probe The N-Acetylprocainamide probe was purified using procedures similar to those described in Example 4 for the digoxin probe. The structure of the caged dicarboxy sili¬ con phthalocyanine-N-acetylprocainamide probe is shown in Fig. 31. Example 16 Synthesis of Caged Dicarboxy Silicon Phthalocyanine-Primidone A. Preparation of Nitroprimidone Primidone, 1.60 g, was dissolved with stirring in 8 ml concentrated sulfuric acid and cooled in ice. A cold solution of 485 μl concentrated nitric acid in 2 ml con¬ centrated sulfuric acid was added over a period of 10 min¬ utes. After 2 hours at 0°C the reaction mixture was poured into ice water neutralized with cold sodium hydrox¬ ide. The precipitate was collected, washed with water and dried in vacuo affording 1.79 g white solid. B. Preparation of Aminoprimidone Nitroprimidone 1.79 g was dissolved with heating in 15 ml concentrated, HCl and 35 ml THF. The solution was allowed to cool to room temperature. A solution of 4.86 SnCl 2 in 3 ml concentrated HCl and 3 ml THF was added over a period of 10 minutes. After stirring at room tempera¬ ture overnight, the reaction mixture was made basic with ammonium hydroxide. The THF layer was separated and evaporated to dryness. The residue was dried in vacuo, stirred in 10 ml THF and centrifuged to remove inorganic material. The clean THF solution was evaporated in vacuo to provide a residue which upon fractional crystallization from THF and petroleum either yielded 519 mg pure amino¬ primidone. C. Preparation of Probe The primidone probe was prepared as follows: 0.8 mg 5-ethyl-5- (4-aminophenyl) hexahydropyrimidine-4, 6-dione (p-aminoprimidone) was placed in 100 μl DMF in a 3.0 μl reaction vial. To the reaction vial was added 1.0 mg caged dicarboxy silicon phthalocyanine (1.0 mg) and 3.1 mg HOBT. To make the final reaction mixture, 3.9 mg EDAC was added along with 150 ml DMF and the resulting mixture mixed thoroughly. The reaction mixture was stored over- night at about 4-8°C. D. Purification of Probe The primidone probe was purified using procedures similar to those described in- Example 3 for the digoxin probe. The structure of the caged dicarboxy silicon phthalocyanine-primidone probe is shown in Fig. 37. Example 17 Synthesis of Caged Dicarboxy Silicon Phthalocyanine-Phenvtoin A. Preparation of Probe The phenytoin probe was prepared as follows: 1.2 mg of diphenylglycine was placed in a 3.0 ml reaction vial and dissolved with 100 μl DMF. In a separate vial, dicar- boxyphthalocyanine (3.0 mg) was dissolved in 400 ml DMF and then transferred to the reaction vial along with 200 μl of wash DMF for a total of 600 μl. To the reaction vial was added 6.1 mg of HOBT, dissolved and mixed well. To make the final reaction mixture, 7.0 mg of EDAC was added and mixed thoroughly. The reaction was stored at 4.0-8.0°C overnight. B. Purification of Probe The phenytoin-phthalocyanine probe was purified using procedures similar to those described in Example 3 for the digoxin probe. The structure of the caged dicarboxy sili¬ con phthalocyanine-phenytoin probe is shown in Fig. 33. Example 18 Rubella Anti-IgG Probe A. Labeling of Goat Anti-Human IgG Caged dicarboxy silicon phthalocyanine dye (12 μmoles) prepared according to Example 1 and purified by DEAE Sephadex chromatography was mixed with 1 ml of pyridine-pyridinium chloride buffer made by mixing 5 ml 1 M HCl with 0.5 ml pyridine. The solution was taken to dryness in a sublimation apparatus and the excess pyridine and pyridinium chloride was removed, thus assuring that all acetate ion present would be removed. The dry resi¬ dual dye was dissolved in anhydrous dichloromethane to make a 3.5 mM solution. The carboxylic acid groups of the dye were converted to the imidazolide by mixing 1 ml of 3.5 mM dye with 760 μl of 0.46 M carbonyl diimidazole and allowing 1.5 hour at room temperature for reaction, after which the solvent was removed .in vacuo. DMF was scavenged free of water and reactive amines by adding carbonyl diimidazole to a final concentration of 0.1 M. To 100 μl of scavenged DMF was added 10 μl of H 2 0 and 100 μl of this mixture was added in the cold to the dry activated dye. After 1 minute this mixture was added to a mixture of 600 μl IgG solution containing 6 mg of goat anti-human IgG and 100 μl of 100 mM phosphate, pH 7.6. The reaction was allowed to proceed for 4.5 hours at room temperature and overnight at 4°C. A portion of the reac¬ tion mixture was equilibrated with 10 mM phosphate, pH 7.6 by two treatments in a Minicon concentrator (Amicon Cor¬ poration, Danvers, MA, USA) and passed through a hydroxy- lapatite column (Bio Rad Laboratories, Richmond, CA, USA) equilibrated with 10 mM phosphate, pH 7.6. Free dye eluted at this stage and the labeled antibody was recov- ered by elution with 100 mM phosphate, pH 7.6. B. Analysis of Probe The labeled antibody was found by absorbance measure¬ ments at 280 nm and 682 nm to contain an average of 1.3 moles of dye/mole of IgG. It was shown to react specifi¬ cally in a solid phase sandwich assay in which adsorbed rubella virus antigen was coated with human anti-rubella which enabled reaction with the labeled antibody. Tran¬ sient-state fluorescence intensity measurements in the 680 nm region were used to quantify the bound labeled anti¬ body. Specificity was further tested by correlation with a standard method. A series of 40 patient samples were run; 4 were negative by both methods, 35 were positive by both while one was positive by the standard method and negative transient state fluorescence. In clinical pathology and medical screening, speci- ficity is defined as the proportion of individuals with negative test results for the disease that the test is intended to reveal, i.e.. true negative results as a proportion of the total number of true negative and false positive results. In this example, by this definition, this assay demonstrated 100% specificity. In addition, sensitivity of a procedure can be defined as that pro¬ portion of individuals with a positive test result for the disease that the test intended to reveal , i.e. , true posi¬ tive results as a proportion of the total true positive and false negative results. These data indicate a 97.2% sensitivity for this assay system. Although we report a relatively small number of samples the performance of the assay demonstrates the use of an antibody labeled with the marker components in a sandwich assay. See Fig. 34. Example 19 Synthesis of Caged Dicarboxy Silicon Phthalocyanine Synthetic Rubella Peptide A. Preparation of Probe A synthetic rubella peptide, for example, a portion of the E-. protein of the rubella virus (Therien strain) , can be synthesized by standard peptide synthesis proce¬ dure. The coupling of caged dicarboxy silicon phthalo¬ cyanine (prepared according to Example 1) to the synthetic rubella peptide was a four step process: 1. Dye activation - Sufficient caged dicarboxy silicon phthalocyanine in dimethylformamide to give a molar ratio of caged dicarboxy silicon phthalocyanine dye to peptide of 1.3 was activated by adding 50 moles of carbonyldiimidazole per mole of dye in dichloromethane to form an imidazole. 2. Decomposition of excess carbonyldiimidazole — The dichloromethane was evaporated from the activation mixture and water was added to decompose the excess carbonyldiimidazole. 3. Coupling to Peptide — The solution was buffered by adding for each μmole of carbonyldiimidazole used 1 μl of a mixture of 100 μl of pyridine, 2.38 ml water and 620 μl of 1 M HCl. The resulting solution was added to the dry peptide. Alternatively, the carbonyldiimidazolide was reacted with the peptide in DMF. B. Purification of Probe Purification of caged dicarboxy silicon phthalo¬ cyanine labelled peptide from the reaction mixture was carried out by high performance liquid chromatography on a reversed phase C 18 column using a water-methanol gradient. Example 20 Immunological Evaluation of Phthalocyanine-Rubella Probe Two assay procedures were performed in order to evaluate the phthalocyanine-Rubella probe. The phthalo¬ cyanine-Rubella Probe was diluted in a 0.01 Tris buffer pH 8.0 containing 0.1 % bovine serum and 0.025% Tween 20. The probe concentration was determined to be 1.1 x 10" 11 M/L. Rubella peptide calibrators were made by diluting in the Tris buffer to the following concentrations: 0.0, 1.0 x 10' 12 , 2.7 x 10 "12 , and 5.4 x 10 "12 , 2.7 x 10 -11 , and 5.4 x 10 "11 . The antibody was made by hyper-immunizing a rabbit with the Rubella peptide. Dilutions were made in the Tris buffer described above. A. Competitive Binding Assay (Sequential Format) To a series of small conical test tubes was added 25 μl Tris buffer, 20 μl antibody solution and 10 μl antibody solution and 10 μl of each peptide calibrator. The tubes were incubated at 35°C for 10 minutes. At this time, 15 μl of probe was added to each tube and incubated an additional 20 minutes at 35°C. After incubation 1.0 ml of Tris buffer was added and transient state polarization measurements were made. The typical inhibition curve is shown in Fig 35. The data obtained clearly demonstrated a sensitivity of 1.0 x 10 "12 M/L of peptide in a homogeneous fluorescence polariza- tion assay. B. Antibody Titration Curve To a series of small conical test tubes, varying dilutions of rubella antibody (20 μl) was incubated with 20 μl Tris buffer and 15 μl probe for 20 minutes at 35°C. After incubation 1.0 ml of Tris buffer was added to each tube and the transient state polarization was measured. The data obtained are shown in Fig. 36. A typical antibody was obtained at a probe concentra¬ tion of 2.0 x 10 "11 M/L. As can be seen from the data, the probe when depolarized in buffer has a polarization of 51 millipolarization units (mP) and when bound to antibody exhibits a polarization of 215 mP, with a dynamic range of 164 mP. Thus, indicating the ability to use a homogeneous polarization assay for detection of rubella virus anti- bodies in human serum samples. Those skilled in the art will recognize that the methods used in the above examples relating to rubella peptide are applicable to other peptides. For example, probes can be made for peptide hormones such as luteiniz- ing hormone, follicular stimulating hormone, human chorio- gonadotropin, thyroid stimulating hormone. Angiotensin I, Angiotensin II, prolactin and insulin. Probes can be made for peptides such as tumor markers (for example, carcino- embryonic antigen) as well. To assist in understanding the invention, the results of a series of experiments have been provided. The above examples relating to the present invention should not, of course, be construed as limiting the scope of the inven¬ tion. Such variations of the invention, now known or later developed, which would fall within the purview of those skilled in the art are to be considered as falling within the scope of the invention as hereinafter claimed.

Claims: Claims 1. A method for determining the presence or amount of a target analyte in a sample comprising the steps: (a) contacting a sample suspected of containing a target analyte with a known quantity of added target analyte or analog thereof linked to a fluorescent probe which comprises a detectably labeled marker component which comprises a fluorophore moiety comprising a lumi¬ nescent substantially planar molecular structure coupled to two solubilizing polyoxyhydrocarbyl moieties, one loca¬ ted on either side of the planar molecular structure; (b) contacting said sample with a receptor capable of specifically recognizing said target analyte; and (c) determining the amount of fluorescent probe linked to added target analyte bound to said receptor or the amount of fluorescent probe linked to added target analyte which is not bound to said receptor. 2. The method of claim 1 further comprising the step of comparing said amount of bound or unbound fluor¬ escent probe with the amount of fluorescent probe in a standard sample free of said target analyte or containing said target analyte in a known amount. 3. The method of claim 1 further comprising dilut- ing the resultant mixture from steps (a) and (b) by an amount of from 2-fold to 100-fold. 4. The method of claim 3 wherein said diluting is by an amount of from about 7-fold to about 50-fold. 5. The method of claim 4 wherein said diluting is by an amount of from about 35-fold. 6. In an immunoassay process to determine the pres¬ ence or concentration of a target analyte in a sample com- prising measuring labeled target analyte or analog thereof or labeled receptor capable of specifically recognizing said target analyte, the improvement comprising employing as a label a fluorescent probe which comprises a detect- ably labeled marker component which comprises a fluoro¬ phore moiety comprising a luminescent substantially planar molecular structure coupled to two solubilizing polyoxy¬ hydrocarbyl moieties, one located on either side of the planar molecular structure. 7. A method for determining the presence or amount of a target analyte in a sample comprising the steps: (a) contacting a sample suspected of containing a target analyte with a first receptor capable of specifi¬ cally recognizing said target analyte to form a complex of said target analyte and said first receptor, said first receptor being labeled with a fluorescent probe which com¬ prises a fluorophore moiety comprising a luminescent sub¬ stantially planar molecular structure coupled to two solu¬ bilizing polyoxyhydrocarbyl moieties, one located on either side of the planar molecular structure; (b) contacting the complex with a second receptor capable of specifically recognizing said target analyte, said second receptor being bound to a solid carrier, to form a complex of said first labeled receptor, said target analyte and said second receptor bound to said solid carrier; and (c) measuring either the amount of labeled first receptor associated with said solid carrier or the amount of unreacted labeled first receptor. 8. The method of claim 7 further comprising the step of separating said solid carrier from said sample and said unreacted labeled first receptor. 9. The method of claim 7 further comprising the step of relating the amount of labeled first receptor measured to the amount of labeled first receptor measured for a control sample free of said target analyte, or relating the amount of labeled first receptor measured with the amount of labeled first receptor measured in samples containing known amounts of target analyte. 10. A method for determining the presence or amount of a target analyte in a sample comprising the steps of: (a) simultaneously contacting a sample sus¬ pected of containing a target analyte with first and second receptors capable of specifically recognizing said target analyte, said first receptor being labeled with a fluorescent probe which comprises a fluorophore moiety comprising a luminescent substantially planar molecular structure coupled to two solubilizing polyoxyhydrocarbyl moieties, one located on either side of the planar mole¬ cular structure and said second receptor being bound to a solid carrier, to form a complex of said first receptor, said target analyte, and said second receptor; and (b) measuring either the amount of labeled first receptor associated with said solid carrier or the amount of unreacted labeled first receptor. 11. The method of claim 10 further comprising the step of separating said solid carrier from said sample and said unreacted labeled first receptor. 12. The method of claim 10 further comprising the step of relating the amount of labeled first receptor measured to the amount of labeled first receptor measured for a control sample free of said target analyte, or relating the amount of labeled first receptor measured with the amount of labeled first receptor measured in samples containing known amounts of target analyte. 13. The method of claim 7 or 10 wherein said first rece p tor is labeled with a first fluorescent probe and said second receptor is labeled with a second fluorescent probe, the first fluorescent probe having a different absorption and emission than the second fluorescent probe, and wherein the absorption of one of the fluorescent probes overlaps with the emission of the other fluorescent probe. 14. The method of claim 1, 6, 7 or 10 wherein said sample is a biological fluid. 15. The method of claim 14 wherein said biological fluid is serum. 16. The method of claim 14 wherein said biological fluid is plasma. 17. The method of claim 14 wherein said biological fluid is whole blood. 18. The method of claim 17 wherein red blood cells in said whole blood have been lysed. 19. The method of claim 18 wherein said red blood cells have been caused to lyse by use of a compound selected from the group consisting of stearyllysolecithin, palmitoyl-lysolecithin and myristoyl-lysolecithin. 20. The method of claim 14 wherein said biological fluid is urine. 21. The method of claim 1, 6, 7 or 10 wherein said target analyte is selected from the group consisting of an antigen, a hapten, and an antibody, and said receptor is selected from the group consisting of an antigen and an antibody. 22. The method of claim 21 wherein said antibody is a monoclonal antibody. 23. The method of claim 1, 6, 7 or 10 wherein said target analyte is a drug or a metabolite of a drug. 24. The method of claim 23 wherein said drug is a steroid, hormone, antiasthmatic, antineoplastic, anti- arrhythmic, anticonvulsant, antiarthritic, antidepressant, or cardiac glycoside. 25. The method of claim 23 wherein said drug is digoxin. 26. The method of claim 23 wherein said drug is N-acetylprocainamide. 27. The method of claim 23 wherein said drug is phenobarbital. 28. The method of claim 23 wherein said drug is primidone. 29. The method of claim 23 wherein said drug is theophylline. 30. The method of claim 23 wherein said drug is thyroxine. 31. The method of claim 23 wherein said drug is digitoxin. 32. The method of claim 1, 6, 7 or 10 wherein said target analyte is a peptide. 33. The method of claim 32 wherein said peptide is rubella virus peptide. 34. The method of claim 32 wherein said peptide is a portion of the E-* . viral protein of rubella virus peptide. 35. The method of claim 1, 6, 7 or 10 wherein said method is capable of detecting target analyte in a con- centration of from about 1 x 10 ~5 M/L to about 1 x 10" 13 M/L. 36. The method of claim 1, 6, 7 or 10 wherein said method is capable of detecting target analyte in a con¬ centration of from about 1 x 10" 10 M/L to about 1 x 10 ~12 M/L. 37. The method of claim 23 wherein said method is capable of detecting drug or metabolite in a concentration of from about 5 x lO" 9 M/L to about 5 x lO '12 M/L. 38. The method of claim 37 wherein said method is capable of detecting drug or metabolite in a concentration of from about 1 x 10 "10 M/L to about 5 x 10 "10 M/L. 39. The method of claim 37 wherein said drug is digoxin. 40. The method of claim 38 wherein said drug is digoxin. 41. The method of claim 32 wherein said method is capable of detecting peptide at a concentration of from about 1 x lO "10 M/L to about 1 x lO" 12 M/L. 42. The method of claim 41 wherein said peptide is rubella virus peptide or a portion thereof. 43. The method of claim 1, 6, 7 or 10 wherein said determining of amount of fluorescent probe is by steady- state fluorescence measurement. 44. The method of claim 1, 6, 7 or 10 wherein said determining of amount of fluorescent probe is by transient state fluorescence measurement. 45. The method of claim 1, 6, 7 or 10 wherein said determining of the amount of fluorescent probe is made by measurement of light at a wavelength of greater than 500 nm. 46. The method of claim 45 wherein said determining of the amount of the fluorescent probe is made by measure- ment of light at a wavelength of greater than 650 nm. 47. The method of claim 45 wherein said determining of the amount of the fluorescent probe is made by measure¬ ment of light at a wavelength of 680 nm. 48. The method of claim 45 wherein said determining of the amount of the fluorescent probe is made by measure¬ ment of light at a wavelength of 690 nm. 49. The method of claim 45 wherein said determining of the amount of the fluorescent probe is made by measure¬ ment of light at a wavelength of greater than about 700 nm. 50. The method of claim 1, 6, 7 or lo wherein said luminescent substantially planar molecular structure com¬ prises a macrocyclic multidentate ligand coordinated to a central atom. 51. The method of claim 1, 6, 7 or 10 wherein one of said two solubilizing polyoxyhydrocarbyl moieties is linked on either side of the plane of the macrocyclic ligand to the central atom. 52. The method of claim 1, 6, 7 or 10 wherein said two solubilizing polyoxyhydrocarbyl moieties comprise axial ligands which coordinate to the central atom. 53. The method of claim 52 wherein said solubilizing polyoxyhydrocarbyl moieties are selected from polyethers, polyols, water soluble carbohydrates, water soluble carbo¬ hydrate derivatives, and water soluble polymers. 54. The method of claim 52 wherein said central atom is capable of forming octahedral coordination complexes. 55. The method of claim 50 wherein said macrocyclic multidentate ligand has a conjugated 7r-electron system. 56. The method of claim 55 wherein said macrocyclic multidentate ligand comprises a nitrogen-containing macrocycle. 57. The method of claim 56 wherein said macrocyclic multidentate ligand is selected from the group consisting of a porphyrin derivative, a porphyrin derivative having one or more bridging carbons replaced by nitrogen, a corrin derivative, a sapphyrin derivative, and a porphy- cene derivative. 58. The method of claim 57 wherein said central atom is selected from the group consisting of silicon, german¬ ium, phosphorus and tin. 59. The method of claim 56 wherein said macrocycle comprises a porphyrin derivative wherein from 1 to 4 of the bridging carbon atoms is replaced by nitrogen. 60. The method of claim 53 wherein said solubilizing polyoxyhydrocarbyl moieties comprise polyethylene glycol or polyethylene glycol derivatives. 61. The method of claim 60 wherein each said poly¬ oxyhydrocarbyl moieties has a molecular weight of about 200 to about 20,000. 62. The method of claim 59 wherein said macrocycle comprises a tetrabenzotriazaporphyrin derivative. 63. The method of claim 62 wherein said macrocycle is selected from tetrabenzotriazaporphyrin, 27-phenyl- tetrabenzotriazaporphyrin, and 27- (p-methylphenyl)tetra¬ benzotriazaporphyrin. 64. The method of claim 58 wherein the central atom is silicon. 65. The method of claim 59 wherein said macrocyclic ligand has a low degree of symmetry so as to enhance the polarization of emission parallel to polarization of absorption. 66. The method of claim 65 wherein said central atom is silicon or germanium. 67. The method of claim 66 wherein said macrocyclic ligand has a lower symmetry than D 4h . 68. The method of claim 67 wherein said macrocyclic ligand has at least one fused aromatic ring. 69. The method of claim 67 wherein said macrocyclic ligand comprises a porphyrin derivative wherein 1 to 3 of the bridging carbon atoms is replaced by nitrogen. 70. The method of claim 68 wherein said macrocyclic ligand comprises a phthalocyanine derivative. 71. The method of claim 68 wherein said macrocycle comprises a tetrabenzotriazaporphyrin derivative. 72. The method of claim 1, 6, 7 or 10 wherein said detectably labelled marker component comprises a fluoro- phore moiety coupled to two solubilizing polyoxyhydro¬ carbyl moieties which in the presence of serum components in aqueous solution is characterized by transient state fluorescence emission having parallel and perpendicular components of substantially the same intensities as with- out serum. 73. The method of claim 72 wherein said fluorophore moiety comprises a tetrabenzotriazaporphyrin derivative. 74. The method of claim 72 wherein said fluorophore moiety comprises a phthalocyanine derivative. 75. The method of claim 1, 6, 7 or 10 wherein said fluorescent probe has a fluorescence polarization of greater than about 10% of the theoretical maximum value for an observable polarization. 76. The method of claim 1, 6, 7 or 10 wherein said fluorescent probe has a decay time in the range of from about 1 nanosecond to about 50 nanoseconds. 77. The method of claim 76 wherein said decay time is in the range of from about 5 nanoseconds to about 20 nanoseconds. 78. The method of claim 1, 6, 7 or 10 wherein said fluorescent probe comprises the caged dicarboxy silicon phthalocyanine digoxin probe of Example 3. 79. The method of claim 1, 6, 7 or 10 wherein said fluorescent probe comprises the caged dicarboxy silicon phthalocyanine digitoxin probe of Example 11. 80. The method of claim 1, 6, 7 or 10 wherein said fluorescent probe comprises the caged dicarboxy silicon phthalocyanine theophylline probe of Example 12. 81. The method of claim 1, 6, 7 or 10 wherein said fluorescent probe comprises the caged dicarboxy silicon phthalocyanine phenobarbital probe of Example 13. 82. The method of claim 1, 6, 7 or 10 wherein said fluorescent probe comprises the caged dicarboxy silicon phthalocyanine thyroxine probe of Example 14. 83. The method of claim 1, 6,. 7 or 10 wherein said fluorescent probe comprises the caged dicarboxy silicon phthalocyanine N-acetylprocainamide probe of Example 15. 84. The method of claim 1, 6, 7 or 10 wherein said fluorescent probe comprises the caged dicarboxy silicon phthalocyanine primidone probe of Example 16. 85. The method of claim 1, 6, 7 or 10 wherein said fluorescent probe comprises the caged dicarboxy silicon phthalocyanine phenytoin probe of Example 17. 86. The method of claim 1, 6, 7 or 10 wherein said fluorescent probe comprises the caged dicarboxy silicon phthalocyanine rubella anti-IgG probe of Example 18. 87. The caged dicarboxy silicon phthalocyanine digoxin probe of Example 3. 88. The caged dicarboxy silicon phthalocyanine digitoxin probe of Example 11. 89. The caged dicarboxy silicon phthalocyanine theophylline probe of Example 12. 90. The caged dicarboxy silicon phthalocyanine phenobarbital probe of Example 13. 91. The caged dicarboxy silicon phthalocyanine thyroxine probe of Example 14. 92. The caged dicarboxy silicon phthalocyanine N-acetylprocainamide probe of Example 15. 93. The caged dicarboxy silicon phthalocyanine primidone probe of Example 16. 9 . The caged dicarboxy silicon phthalocyanine phenytoin probe of Example 17. 95. The caged dicarboxy silicon phthalocyanine rubella anti-IgG probe of Example 18.

Inventors: ARRHENIUS PETER OLOF GUSTAF, DANDLIKER WALTER BEACH, DEVLIN ROBERT FRANCIS, ARRHENIUS, PETER, OLOF, GUSTAF, DANDLIKER, WALTER, BEACH, DEVLIN, ROBERT, FRANCIS
Applicants: DIATRON CORP, DIATRON CORPORATION
Application year: 1993
Main classification: C07H23
IPC codes: A61K49, C07F7, G01N33